cluster,concept,cuis
87,copd assessment test ( cat ) score,C0007450;C0325090;C0449820;C0524517;C1443200;C3665481;C4050231;C4050461;C4284282
87,cat total score,C0007450;C0325090;C0524517;C1443200;C2964552;C3665481;C4050461;C4284282
86,homa - ir  median ( qnmbr  qnmbr ),C0022065;C0022071;C0549183;C0876920;C1448132;C2347635;C2348144;C2939193
86,bdmard - ir,C0022065;C0022071;C1448132
85,lipoprotein ( a ) ( mg / dl ),C0065058;C0125953;C0439269;C1096202;C1439335
85,lipoprotein ( a )  median ( ql  qnmbr )  nmol / l,C0065058;C0125953;C0439282;C0549183;C0876920;C1096202;C1439335;C2347635;C2348144;C2939193
84,previous balloon angioplasty  n ( % ),C0002996;C0002997;C0205156;C1552607
84,balloon angioplasty — no . ( % ),C0002996;C0002997
83,coronary heart disease ( % ),C0010054;C0010068;C1956346
83,coronary heart disease,C0010054;C0010068;C1956346
82,myocardial ischaemia,C0010054;C0151744
82,ischemic heart disease  %,C0010054;C0151744
81,nt - probnp  median ( iqr )  pg / ml,C0439297;C0549183;C0669479;C0754710;C0876920;C2347635;C2348144;C2939193
81,change in nt - probnp at nmbr months ( log - transformed ),C0392747;C0443172;C0669479;C0754710;C1705241;C4319952
80,recent surgery or trauma,C0038894;C0038895;C0332185;C0543467;C1274039
80,planned valve surgery  n ( % ),C0038894;C0038895;C0184252;C0543467;C1186983;C1274039;C1301732;C1704414;C3888056
79,ace - i or arb use,C0021966;C0221138;C1452534;C4284014
79,ace - i / arb  ( % ),C0021966;C0221138;C1452534;C3888198;C4284014
78,tc / hdl - c ratio,C0039411;C0040642;C0041405;C0041698;C0456603;C1547037;C1824670;C3272447;C3715113;C4522122
78,tc / hdl - c,C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C3715113;C4522122
77,bl updrs : low,C0005918;C0006413;C1552663;C2827109;C3639721
77,bl updrs : high,C0005918;C0006413;C1552663;C2827109;C3639721
76,valsartan / hctz  n / n ( % ),C0020261;C0216784
76,valsartan / hctz,C0020261;C0216784
75,clopidogrel / ticlopidine,C0040207;C0070166
75,clopidogrel  ticlopidine  or prasugrel,C0040207;C0070166
74,ldl cholesterol at baseline ( mmol / l ) * ldl cholesterol at screening,C0023824;C0168634;C0202117;C1442488;C1532563
74,baseline ldl cholesterol,C0023824;C0168634;C0202117;C1442488
73,history of amputation — no . ( % ),C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062
73,history of amputation,C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062
72,fasting insulin — / tiu / ml §,C0015663;C0021641;C0439526;C1533581;C1579433;C1705224;C3714501;C3887665
72,fasting insulin,C0015663;C0021641;C1533581;C1579433;C3714501
71,urgent cor revasc,C0018787;C0056331;C0378365;C0439609;C3272275
71,cor revasc,C0018787;C0056331;C0378365
70,concomitant antihyperglycaemic drugs  n ( % ),C0013227;C0020616;C0521115;C3687832
70,antihyperglycemic medication usage,C0013227;C0020616;C0457083;C3244316;C4284232
69,cv death or first hhf,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
69,cv death  ml  or stroke,C0011065;C0439526;C1306577;C1705224;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775
68,median albumin / creatinine ratio ( g / mg ),C0024671;C0026410;C0439267;C0439269;C0486293;C0549183;C0876920;C1318293;C1960952;C2346927;C2347635;C2348144;C2939193;C4321396;C4521761
68,high - sensitivity crp — mg / liter | |,C0024671;C0026410;C0439269;C0475211;C1441604;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
67,infliximab nmbr mg / kg,C0053917;C0439272;C0666743;C1334884
67,infliximab - naive ( n = nmbr ),C0053917;C0666743;C1334884
66,current ( nmbr + cigs / day ),C0053917;C0332173;C0439228;C0439505;C0521116;C1334884;C1570610;C1705970
66,current (  nmbr cigs / day ),C0053917;C0332173;C0439228;C0439505;C0521116;C1334884;C1570610;C1705970
65,abatacept monotherapy ( n = nmbr ),C0053917;C1334884;C1619966
65,abatacept ( n = nmbr * ),C0053917;C1334884;C1619966
64,sbp < nmbr mmhg and dbp < nmbr mmhg,C0053917;C0085805;C0439475;C1334884
64,change in sbp ( nmbr months ),C0053917;C0085805;C0392747;C0439231;C0443172;C1334884;C1705241;C4319952
63,vascular territory # nmbr,C0005847;C0053917;C1301808;C1334884;C1558950;C1801960;C2983136
63,nmbr vessels or left main,C0005847;C0053917;C1334884
62,vorapaxar n = nmbr,C0053917;C1334884;C2974521
62,vorapaxar group ( n = nmbr ),C0053917;C0441848;C1334884;C2974521
61,diet plus pravastatin group ( n = nmbr ),C0012155;C0012159;C0053917;C0085542;C0332287;C0441848;C1334884;C1519433;C2983588;C3668949
61,diet + pravastatin ( n = nmbr ),C0012155;C0012159;C0053917;C0085542;C1334884;C1519433;C2983588;C3668949
60,"nmbr - aminosalicylates ’ i "" i ‘",C0021966;C0053917;C0221138;C0368663;C1334884
60,i & ii : fevnmbr > nmbr % predicted,C0021966;C0053917;C0221138;C1334884;C1710602;C4082587
59,north america n z nmbr,C0028405;C0053917;C1334884
59,north america hr ( nmbr % cl ),C0028405;C0053917;C0596019;C1334884
58,nmbr - h pmg ( mg / dl ),C0033727;C0053917;C0369286;C0439269;C0441932;C0564385;C1334884;C4528284
58,after nmbr h,C0033727;C0053917;C0369286;C0441932;C0564385;C1334884;C4528284
57,amlodipine nmbrmg / v = nmbr,C0051696;C0053917;C1334884
57,amlodipine / vaisartan ( n = nmbr ),C0051696;C0053917;C1334884
56,sita nmbr + pio nmbr,C0030800;C0053917;C1334884;C2347712
56,sita / pio nmbr / nmbr,C0030800;C0053917;C1334884;C2347712
55,liraglutide nmbr . nmbr mg / day ( n = nmbr ),C0053917;C0439422;C1334884;C1456408
55,liraglutide ( n = nmbr  nmbr ),C0053917;C1334884;C1456408
54,ez / simva n = nmbr n ( % ),C0053917;C0206578;C1334884
54,anmbr + ez n = nmbr,C0053917;C0206578;C1334884
53,apob : apoa - nmbr ratio,C0003592;C0003593;C0053917;C0456603;C0523508;C1334884;C1547037;C3252643;C4553344;C4553379
53,< nmbr . nmbr mmol / liter apob : apoa - l ratio,C0003592;C0003593;C0053917;C0456603;C0475211;C0523508;C1334884;C1532563;C1547037;C3252643;C4553344;C4553379
52,visit nmbr ldl cholesterol strata,C0023824;C0053917;C0202117;C0545082;C1334884;C1512346;C2826704
52,calculated ldl cholesterol ( week nmbr ),C0023824;C0053917;C0202117;C0332174;C0439230;C0444686;C1334884;C1441506
51,fibrinolysis primary pci ( n = nmbr ) ( n = nmbr ) no . of patients / total no . ( % ),C0016017;C0053917;C0205225;C0439612;C0439631;C1305868;C1334884;C4049621
51,fibrinolysis ( n = nmbr ),C0016017;C0053917;C1305868;C1334884
50,pain vas  nmbr - nmbr mm,C0042815;C0053917;C1334884;C4330985;C4554674
50,pain ( nmbr - nmbr mm vas ),C0042815;C0053917;C1334884;C4330985;C4554674
49,physician global assessment ( nmbr - nmbr mm vas ),C0042815;C0053917;C1334884;C3536884;C3827561;C4050369;C4330985;C4554674
49,patient global assessment of disease activity ( vas nmbr - nmbr mm ),C0042815;C0053917;C1334884;C3536884;C3827561;C4054228;C4330985;C4554674
48,ind nmbr gg q . d . n / n ( % ),C0017454;C0018370;C0053917;C1334884;C4049864
48,gly nmbr . nmbr gg b . i . d n / n ( % ),C0017454;C0018370;C0053917;C0152277;C1334884;C1415124
47,clopidogrel ( n = nmbr ),C0053917;C0070166;C1334884
47,clopidogrel ( n = nmbr  nmbr ),C0053917;C0070166;C1334884
46,vorapaxar placebo nmbr - yr . km % rate,C0032042;C0053917;C0439234;C0871208;C1334884;C1521828;C1696465;C1706408;C2974521;C3887676
46,vorapaxar placebo nmbr - yr %,C0032042;C0053917;C0439234;C1334884;C1696465;C1706408;C2974521
45,triglycerides > nmbr mg / dl,C0041004;C0053917;C0439269;C1334884
45,triglycerides ( week nmbr ) a,C0041004;C0053917;C0332174;C0439230;C1334884
44,non - caucasian eze / simva ( „ = nmbr },C0007457;C0043157;C0053917;C1334884;C1518422
44,caucasian simva ( „ = nmbr },C0007457;C0043157;C0053917;C1334884
43,framingham nmbr - year cv risk score,C0035647;C0053917;C0439234;C0439508;C0449820;C1334884;C3166866;C3538987;C4048877;C4050231;C4318503;C4552904
43,> nmbr additional cv risk factorsnmbr,C0035647;C0053917;C1334884;C1524062;C3538987;C4048877;C4318503;C4552904
42,crcl at baseline < nmbr ml / min,C0053917;C0168634;C0439445;C1334884;C1442488;C1846718
42,baseline albumin / creatinine ratio in nmbr classes,C0053917;C0168634;C0456387;C0486293;C1318293;C1334884;C1442488;C1518526;C1705943;C4019422
41,therapy ( asa nmbr / placebo nmbr ),C0004057;C0032042;C0039798;C0053917;C0087111;C1334884;C1363945;C1696465;C1706408;C3853627
41,therapy ( asa nmbr  nmbr / placebo nmbr ),C0004057;C0032042;C0039798;C0053917;C0087111;C1334884;C1363945;C1696465;C1706408;C3853627
40,alteplase group ( n = nmbr ),C0032143;C0053917;C0441848;C1334884
40,alteplase ( n = nmbr ),C0032143;C0053917;C1334884
39,no p - blocker intake at randomisation ( n = nmbr ),C0034656;C0053917;C0369773;C1334884;C1512806;C2603361
39,coronary revascularization nmbr days after randomization,C0034656;C0053917;C0439228;C0877341;C1334884
38,hdl cholesterol ( week nmbr ) a,C0023822;C0053917;C0332174;C0392885;C0439230;C1334884
38,> nmbr . nmbr hdl cholesterol level,C0023822;C0053917;C0201950;C0392885;C0428466;C0441889;C0456079;C1334884;C1547707;C2946261;C3715113
37,czp nmbr mg ( n nmbr nmbr ),C0024671;C0026410;C0053917;C0054841;C0439269;C1334884;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
37,czp nmbr mg  % ( n / n ),C0024671;C0026410;C0053917;C0054841;C0439269;C1334884;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
36,nmbr mg clopidogrel load,C0024671;C0026410;C0053917;C0070166;C0439269;C1334884;C1550025;C1704782;C1708715;C1960952;C2346927;C4321396;C4521761
36,intended clopidogrel dose nmbr mg,C0024671;C0026410;C0053917;C0070166;C0178602;C0439269;C0869039;C1114758;C1283828;C1334884;C1551357;C1960952;C2346927;C4321396;C4521761
35,cause of heart failure — no . ( % ),C0015127;C0018801;C0018802;C1524003;C4554158
35,cause of heart failure,C0015127;C0018801;C0018802;C1524003;C4554158
34,qualifying type of atherosclerosis — no . ( % ),C0003850;C0004153;C0332307;C1514624;C1547052
34,large - artery atherosclerosis,C0003850;C0004153;C0226003
34,atherosclerosis^  n ( % ),C0003850;C0004153
33,index event — no . ( % ),C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
33,index event asymptomatic or unconfirmed,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
33,index event  %,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
32,peripheral arterial disease — no . ( % ) §,C0085096;C1704436
32,peripheral arterial disease  n ( % ),C0085096;C1704436
32,any peripheral arterial disease,C0085096;C1704436
31,white / european,C0007457;C0043157;C0220938;C0239307;C1535514
31,white  n ( % ),C0007457;C0043157;C0220938
31,caucasian simva,C0007457;C0043157
30,no ascvd + additional cv risk factors  n ( % ),C0035648;C1524062;C1553898;C3538987;C3665365;C4048877;C4318503
30,cv risk factor - no . ( % ),C0035648;C3538987;C4048877;C4318503
30,cv risk factor,C0035648;C3538987;C4048877;C4318503
29,fev  at baseline,C0168634;C1442488;C3714541
29,baseline fvc  l,C0168634;C1442488;C3714541
29,baseline fev  ( l ),C0168634;C1442488;C3714541
28,receptor blockers  n ( % ) baseline lipid and apolipoprotein levels,C0023779;C0168634;C0597357;C1442488
28,metabolic syndromenmbr baseline lipids  mg / dl,C0023779;C0168634;C0311400;C0439269;C1442488;C1524026;C2707259
28,baseline lipids  mean ± sd ( mmol / l ),C0023779;C0168634;C0444504;C1442488;C1532563;C2347634;C2348143;C2699239
27,diuretic drugs ( excluding antialdosterone ),C0012798;C0013227;C3687832
27,diuretic drugs  n ( % ),C0012798;C0013227;C3687832
27,diuretic drugs,C0012798;C0013227;C3687832
26,warfarin ( n = nmbr ),C0043031;C0053917;C1334884
26,> nmbr yr warfarin experience,C0043031;C0053917;C0237607;C0439234;C0596545;C1334884
26,> nmbr days warfarin,C0043031;C0053917;C0439228;C1334884
25,standard control ( n = nmbr ) no . of patients ( percent ),C0053917;C0243148;C1334884;C1442989;C1550141;C1882979;C2587213;C2828392;C3274648;C4553389
25,control group ( n = nmbr ),C0053917;C0243148;C0441848;C1334884;C1550141;C1882979;C2587213;C3274648;C4553389
25,( % ) control ( nmbr ),C0053917;C0243148;C1334884;C1550141;C1882979;C2587213;C3274648;C4553389
24,indacaterol nmbr ug versus placebo,C0041573;C0053917;C0439211;C1334884;C1722260
24,indacaterol nmbr ug versus indacaterol nmbr ug,C0041573;C0053917;C0439211;C1334884;C1722260
24,indacaterol nmbr ug ( n = nmbr ),C0041573;C0053917;C0439211;C1334884;C1722260
23,no use of nmbr - asa compounds,C0004057;C0053917;C0205198;C1334884;C1524063;C1706082;C3853627
23,aspirin only ( n = nmbr  nmbr ),C0004057;C0053917;C0205171;C1334884;C1720467
23,aspirin - erdp ( n = nmbr  nmbr ),C0004057;C0053917;C1334884
22,clopidogrel plus aspirin ( n = nmbr ),C0004057;C0053917;C0070166;C0332287;C1334884
22,aspirin nmbr clopidogrel,C0004057;C0053917;C0070166;C1334884
22,aspirin + clopidogrel ( n = nmbr ) nmbr . nmbr,C0004057;C0053917;C0070166;C1334884
21,atenolol n = nmbr no . ( % ),C0004147;C0053917;C1334884
21,atenolol n = nmbr,C0004147;C0053917;C1334884
21,atenolol ( « = nmbr nmbr ),C0004147;C0053917;C1334884
20,events treatment ( nmbr ),C0039798;C0053917;C0087111;C0441471;C1334884;C1522326;C1533734;C1705169;C3538994;C3541888;C3887704
20,epa treatment ( n = nmbr ),C0039798;C0053917;C0087111;C1334884;C1522326;C1533734;C1705169;C3538994;C3887704
20,dpp - nmbr inhibitor therapy,C0039798;C0053917;C0087111;C1334884;C1363945;C1414174;C1999216
19,ticagrelor nmbr mg vs . placebo hr ( nmbr % ci ),C0024671;C0026410;C0053917;C0439269;C1334884;C1960952;C1999375;C2346927;C4321396;C4521761
19,ticagrelor nmbr mg nmbr yr km %,C0024671;C0026410;C0053917;C0439234;C0439269;C1334884;C1960952;C1999375;C2346927;C3887676;C4321396;C4521761
19,ticagrelor  nmbr mg ( n = nmbr ),C0024671;C0026410;C0053917;C0439269;C1334884;C1960952;C1999375;C2346927;C4321396;C4521761
18,screening prebronchodilator fevnmbr  l,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599602
18,screening % reversibility fevnmbr,C0220908;C0220909;C0449261;C1698960;C1710031;C1710032;C1710477;C2348164
18,screening % predicted fevnmbr,C0220908;C0220909;C0681842;C1698960;C1710031;C1710032;C1710477;C1882327;C2348164
18,age at screening,C0001779;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
17,ppi use ( p = nmbr - nmbrt ),C0358591;C0871125;C3811894
17,ppi but no aspirin,C0358591;C0871125;C3811894
17,nontrial ppi,C0358591;C0871125;C3811894
17,non - study ppi use,C0358591;C0557651;C0871125;C1518422;C2603343;C3811894
16,weight ( range ) ( kg ),C0005910;C0022718;C0043100;C0439209;C1305866;C1514721;C1705104;C2348147;C3542016;C4054209
16,weight  median ( interquartile range )  kg,C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C1711350;C2347635;C2348144;C2939193;C4054209
16,weight  mean ± sd ( kg ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
16,mean weight  kg ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
15,gfr ( mdrd ) ( ml / min / nmbr - nmbr mnmbr ),C0017654;C0053917;C0439445;C1334884;C1424601;C3839656
15,estimated gfr ( ml / min / nmbr . nmbr mnmbr ) ^ |,C0017654;C0053917;C0439445;C0750572;C1334884;C1424601
15,estimated gfr  ml min - nmbr nmbr . nmbr m - nmbr ( sd ) a,C0017654;C0053917;C0369637;C0439445;C0441923;C0750572;C1334884;C1424601;C2699239
15,estimated gfr  < nmbr ml min - nmbr nmbr . nmbr m - nmbr  n ( % ) a,C0017654;C0053917;C0369637;C0439445;C0441923;C0750572;C1334884;C1424601
14,omega - nmbr fatty acid ( n = nmbr ),C0015684;C0053917;C1334884;C1719844
14,omega - nmbr fatty acid,C0015684;C0053917;C1334884;C1719844
14,number omega - nmbr number placeb fatty acid,C0015684;C0053917;C0237753;C0449788;C1334884;C1719844
14,b digit symbol substitution  omega - nmbr fatty acids vs placebo,C0015684;C0053917;C0582802;C0679214;C1334884;C1555721;C1698987;C1706204;C1719844;C3241971
13,nmbr to < nmbr kg / mnmbr,C0022718;C0053917;C0439209;C1334884;C4054209
13,nmbr - nmbr . nmbr kg / mnmbr,C0022718;C0053917;C0439209;C1334884;C4054209
13,bmi > nmbr kg / mnmbr ( % ),C0022718;C0053917;C0439209;C0578022;C1334884;C4054209
13,bmi ( kg / mnmbr ) < nmbr,C0022718;C0053917;C0439209;C0578022;C1334884;C4054209
12,total patients n = nmbr,C0030705;C0053917;C0439175;C0439810;C1334884
12,score > nmbr %  % of patients,C0030705;C0053917;C0449820;C1334884;C4050231
12,rate / nmbr patient - years,C0030705;C0053917;C0439234;C0871208;C1334884;C1521828
12,patients with > nmbr exacerbations resulting in hospital admission,C0030705;C0053917;C1334884;C4086268
11,sfc nmbr / nmbr mg twice daily ( n = nmbr ),C0024671;C0026410;C0053917;C0439269;C0585361;C1334884;C1960952;C2346927;C4321396;C4521536;C4521761
11,middle tertile ( range  nmbr . nmbr - nmbr . nmbr mg / dl  mean ± sd  nmbr . nmbr ± nmbr . nmbr mg / dl ),C0024671;C0026410;C0053917;C0439269;C0444504;C0444598;C0549183;C1334884;C1514721;C1552826;C1960952;C2346927;C2347634;C2348143;C2348147;C2699239;C3539687;C3542016;C4321396;C4521761
11,glycopyrronium nmbr mg ( n = nmbr ),C0024671;C0026410;C0053917;C0439269;C1334884;C1960952;C2346927;C3814772;C4321396;C4521761
11,eze / simva nmbr / nmbr mg ( n = nmbr ),C0024671;C0026410;C0053917;C0439269;C1334884;C1960952;C2346927;C4321396;C4521761
10,tofacitinib nmbr mg two times a day,C0024671;C0026410;C0053917;C0439269;C1334884;C1960952;C2346927;C2930696;C4321396;C4521761
10,tofacitinib nmbr mg twice daily n = nmbr,C0024671;C0026410;C0053917;C0439269;C0585361;C1334884;C1960952;C2346927;C2930696;C4321396;C4521761
10,tofacitinib nmbr mg bid [n = nmbr |,C0024671;C0026410;C0053917;C0439269;C1334884;C1960952;C2346927;C2930696;C4321396;C4521761
10,tofacitinib  nmbr mg ( n = nmbr ),C0024671;C0026410;C0053917;C0439269;C1334884;C1960952;C2346927;C2930696;C4321396;C4521761
9,left ventricular ejection fraction  % af history,C0019664;C0019665;C0262512;C0262926;C0344434;C0428772;C0488728;C1705255;C2004062;C4049859
9,history of symptomatic,C0019664;C0019665;C0231220;C0262512;C0262926;C1705255;C2004062
9,history of second prior mi,C0019664;C0019665;C0205436;C0262512;C0262926;C0332152;C0457385;C0565930;C1561503;C1705190;C1705255;C2004062;C2826257;C3810814
9,history of coronary revascularization,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
9,clinical history,C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062
8,with placebo ( n nmbr nmbr ),C0032042;C0053917;C1334884;C1696465;C1706408
8,placebo nmbr year km ( % ),C0032042;C0053917;C0439234;C0439508;C1334884;C1696465;C1706408;C3887676
8,placebo n = nmbr subjects,C0032042;C0053917;C1334884;C1696465;C1706408
8,placebo event rate ( n = nmbr )  %,C0032042;C0053917;C0441471;C0871208;C1334884;C1521828;C1696465;C1706408;C4019010
8,nmbr placebo n = nmbr,C0032042;C0053917;C1334884;C1696465;C1706408
7,smoking pack year ( years ) fl,C0037369;C0439234;C0439508;C0453996;C1277691;C1300812;C1708024;C1881674
7,smoking pack - years,C0037369;C0453996;C1277691;C1881674
7,smoking in the past year,C0037369;C0453996;C1881674;C4086728
7,smoking : ex - smoker,C0037369;C0453996;C1881674
7,smoking ( a ),C0037369;C0453996;C1881674
7,mean ( sd ) duration of smoking  pack years,C0037369;C0444504;C0449238;C0453996;C1277691;C1881674;C2347634;C2348143;C2699239;C2926735
6,mean ( sd ) body mass index  kg / mnmbr,C0005893;C0022718;C0439209;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239;C4054209
6,body mass index ( kg / mnmbr ) - mean ± sd,C0005893;C0022718;C0439209;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239;C4054209
6,body mass index ( bmi )  kg / mnmbr,C0005893;C0022718;C0439209;C0578022;C1305855;C4054209
6,body mass index  median  ( nmbrth — nmbrth percentiles )  kg / mnmbr,C0005893;C0022718;C0439209;C0549183;C0578022;C0876920;C1264641;C1305855;C2347635;C2348144;C2939193;C4054209
6,body mass index  kg / mnmbr  median ( qnmbr  qnmbr ),C0005893;C0022718;C0439209;C0549183;C0578022;C0876920;C1305855;C2347635;C2348144;C2939193;C4054209
6,body - mass index ( kg / mj ) previous diagnosis,C0005893;C0022718;C0332132;C0439209;C0439254;C0578022;C1305855;C4054209;C4284025
5,mean age  years ( nmbr % ci ),C0008107;C0053917;C0444504;C1334884;C1510829;C2347634;C2348143;C3259781
5,mean ( nmbr % ci ) difference vs saxa + dapa + met,C0008107;C0053917;C0444504;C1334884;C1705241;C1705242;C2347634;C2348143;C3259781
5,hr ( nmbr % ci ) p value for interaction *,C0008107;C0053917;C1334884;C1704675;C1709380;C3259781
5,hazard ratio for event ( nmbr % ci ),C0008107;C0053917;C0441471;C1334884;C2985465;C3259781;C4019010
5,( nmbr % ci] nmbr,C0008107;C0053917;C1334884;C3259781
5,( nmbr % ci ) p value,C0008107;C0053917;C1334884;C1709380;C3259781
4,severity of the disease ( gold nmbr )  n ( % ),C0018026;C0053917;C0521117;C1304897;C1334884
4,severity of airflow limitation ( gold nmbr - nmbr )  n ( % ),C0018026;C0053917;C0231999;C0439793;C0443288;C0449295;C0522510;C1304897;C1334884
4,severe ( gold nmbr ),C0018026;C0053917;C0205082;C1304897;C1334884;C4050465;C4050466
4,moderate ( gold nmbr ),C0018026;C0053917;C0205081;C1304897;C1334884;C1881878;C4049705;C4049706;C4085643;C4321335
4,gold nmbr groups  n ( % ),C0018026;C0053917;C1304897;C1334884
4,gold nmbr groups,C0018026;C0053917;C1304897;C1334884
3,recurrent heart failure,C0018801;C0018802;C1455761;C2945760;C4554158
3,previous heart failure,C0018801;C0018802;C0205156;C1552607;C4554158
3,hospitalized for heart failure during that time period,C0018801;C0018802;C0701159;C4554158
3,heart failure — no . ( % ),C0018801;C0018802;C4554158
3,heart failure nyha ii - iii,C0018801;C0018802;C0439070;C1275491;C1705160;C1710602;C4082587;C4554158
3,heart failure ( class l - lll ),C0018801;C0018802;C0456387;C1261077;C1518526;C1705943;C4554158
3,cardiac failure  n ( % ),C0018801;C0018802
2,treatment difference  ml,C0039798;C0087111;C0439526;C1522326;C1533734;C1705169;C1705224;C1705241;C1705242;C3538994;C3887665;C3887704
2,treatment after admission,C0039798;C0087111;C0184666;C0809949;C1522326;C1533734;C1705169;C3538994;C3887704
2,subgroup by treatment interaction p - value,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C1709380;C3538994;C3887704
2,randomised treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
2,pretreatment / concomitant treatment,C0039798;C0087111;C0521115;C1522326;C1533734;C1550147;C1705169;C2709094;C3538994;C3539075;C3539076;C3887704
2,location of treatment center,C0039798;C0087111;C0205099;C1522326;C1533734;C1705169;C3538994;C3887704
2,inadequate response / intolerance to prior therapy  %,C0039798;C0087111;C0205412;C0231199;C0332152;C0439856;C0871261;C1363945;C1704632;C1706817;C1744706;C2355652;C2911692
2,antithrombotic therapy,C0039798;C0087111;C1363945
1,normal ( egfr > nmbr ),C0053917;C0205307;C0231683;C0439166;C1334884;C1739039;C2347086;C3811844;C3812682;C4553972
1,egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr n = nmbr ( nmbr . nmbr % ),C0053917;C0439445;C1334884;C1739039;C3811844;C3812682
1,egfr nmbr - nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr  nmbr ),C0053917;C0439445;C1334884;C1739039;C3811844;C3812682
1,egfr < nmbr ml / min / nmbr . nmbr mnmbr ( mdrd ),C0053917;C0439445;C1334884;C1739039;C3811844;C3812682;C3839656
1,egfr < nmbr  n ( % ),C0053917;C1334884;C1739039;C3811844;C3812682
1,egfr ( mumin / nmbr . nmbr mnmbr ),C0053917;C1334884;C1739039;C3811844;C3812682
1,egfr  ml min nmbr nmbr . nmbr m nmbr,C0053917;C0369637;C0439445;C0441923;C1334884;C1739039;C3811844;C3812682
1,> nmbr to < nmbr egfr  ml / min / nmbr . nmbr mnmbr a,C0053917;C0439445;C1334884;C1739039;C3811844;C3812682
0,≥ nmbr . nmbr to < nmbr . nmbr years,C0053917;C0439234;C1334884
0,yes  non - insulin - treated,C1549445;C1705108;C1710701
0,years since pah diagnosis,C0439234
0,years since menopause,C0439234
0,years [range],C0439234;C1514721;C2348147;C3542016
0,years  mean ( sd ),C0439234;C0444504;C2347634;C2348143;C2699239
0,wrist fracture,C0435630;C4553927
0,with revascularisation,C0581603
0,who / idf ifg,C1334085;C1708411
0,week nmbr mean 士 sd,C0053917;C0332174;C0439230;C0444504;C1334884;C2347634;C2348143;C2699239
0,week nmbr fpg  mean ( s . e . ),C0053917;C0332174;C0439230;C0444504;C1334884;C2347634;C2348143
0,vitamin k antagonist ( e . g . warfarin / coumarol ),C1096489;C2267235
0,visits nmbrenmbr,C0545082;C1512346
0,very severe n z nmbr,C0053917;C1334884;C3641272;C4050419
0,verapamil sr n = nmbr no . ( % ),C0053917;C1334884;C1527129
0,verapamil sr n = nmbr,C0053917;C1334884;C1527129
0,valvular disease ( % ),C3258293
0,urine albumin - to - creatinine ratio - no . ( % ) § §,C0455271;C1318330
0,urine albumin - to - creatinine ratio,C0455271;C1318330
0,urinary albumin / creatinine ratio  median mg / g ( range ),C0455271;C0549183;C0876920;C1300563;C1318330;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
0,urinary albumin - to - creatinine ratio^,C0455271;C1318330
0,urgent coronary revascularization,C0439609;C0877341;C3272275
0,unknown type,C0332307;C0439673;C1547052;C3541433;C4050014
0,unknown,C0439673;C3541433;C4050014
0,unbound pcsknmbr ( nmol / l ),C0439282
0,unacceptable adverse events,C0877248;C1705413;C1883420
0,uacra  mg / g  n ( % ),C1300563
0,uacr ( mgg - nmbr ),C0053917;C1334884
0,uacr  mg / mmol ( interquartile range ) b,C0567349;C1711350;C2348885
0,type of treatment  n ( % ),C0455708
0,type of mi ( % ),C0332307;C1547052;C3810814
0,type of event — no . ( % ),C1561488
0,type nmbr diabetes 一 no . ( % ),C0053917;C1320657;C1334884
0,type nmbr diabetes mellitus ’,C0053917;C1320657;C1334884
0,type nmbr diabetes duration  years,C0053917;C0439234;C0449238;C1320657;C1334884;C2926735
0,type nmbr diabetes duration  mean ( sd )  years,C0053917;C0439234;C0444504;C0449238;C1320657;C1334884;C2347634;C2348143;C2699239;C2926735
0,type nmbr diabetes,C0053917;C1320657;C1334884
0,triple - vessel disease  n ( % ),C0856738
0,trend / het . test,C1521798;C4554533
0,treatment duration  days,C0439228;C0444921;C3259042
0,total study population ( n = nmbr  nmbr ),C0053917;C0439175;C0439810;C0557651;C1334884;C2348561;C2603343;C3258257
0,total n = nmbr n ( % ),C0053917;C0439175;C0439810;C1334884
0,total invasive cancer,C0439175;C0439810;C0677898
0,total group ( n = nmbr ),C0053917;C0439175;C0439810;C0441848;C1334884
0,total gadolinium - enhancing lesion count  no . ( % ),C0439175;C0439810;C1333400
0,total cholesterol ( week nmbr ),C0053917;C0201950;C0332174;C0439230;C0543421;C1334884
0,total cholesterol ( mg / dl )  mean + sd  available for nmbr patients,C0201950;C0439269;C0444504;C0543421;C2347634;C2348143;C2699239
0,total chol  mg / dl,C0201950;C0439175;C0439269;C0439810
0,tnmbrdm duration ( years ),C0439234;C0449238;C2926735
0,tnl ultrapositive > nmbr . nmbr pg / l  nmbr = nmbr,C0053917;C0439278;C1334884;C1540071
0,timi major / minor,C4441842
0,time to admission  min,C0702093;C1524029;C3813700;C3854258;C3854259
0,time of symptom onset to randomization ( hrs ),C1320528
0,time of symptom onset to balloon inflation ( hrs ),C1320528
0,time from onset to randomization  h  mean ± sd,C0449244
0,three or more drugs,C0205449
0,three - vessel disease,C3272265
0,third heart sound  n ( % ),C0232237;C0232278
0,tg < nmbr  hdl > nmbr ( n = nmbr ),C0053917;C0337445;C1334884;C3715113
0,tg  mmol / l [mg / dl],C0337445;C3642216;C3898312
0,tertile nmbr ( nmbr . nmbr - nmbr . nmbr pg / ml ) n = nmbr,C0053917;C0439297;C1334884
0,tertile nmbr,C0053917;C1334884
0,terminal ileum,C0227327
0,tender joint count ( nmbr - nmbr ),C0053917;C0451530;C1334884
0,tender joint count  of nmbr,C0053917;C0451530;C1334884
0,systemic corticosteroids  n ( % ) a,C4053960
0,symptom onset to start of reperfusion treatment : tenecteplase or arterial sheath insertion !,C4086878
0,symbol digit score,C0449820;C0582802;C0679214;C1698987;C3241971;C4050231
0,subjects randomized,C0681850;C1550501;C1706203;C2349001;C2697811
0,stroke risk score,C0449820;C1277291;C4050231
0,stiffness subscale,C0427008
0,standard care ( n = nmbr ),C0053917;C1334884;C1442989;C1947933;C2828392
0,standard ( n = nmbr ),C0053917;C1334884;C1442989;C2828392
0,st - segment elevation mi,C0520886;C3810814
0,st - elevation mi,C0520886;C3810814
0,south asian,C1519427
0,smoking status ( % ),C1519386
0,smoking history — no . ( % ),C1519384
0,smoking history ( ever ),C1519384;C3887636
0,smoking history  pack - years  mean ( sd ),C0444504;C1277691;C1519384;C2347634;C2348143;C2699239
0,small vessel,C0225988
0,single vessel coronary artery disease *,C0581374
0,simva n = nmbr n ( % ),C0053917;C1334884
0,simplified disease activity index,C3869582
0,shs  mean nmbr sd,C0053917;C0444504;C1334884;C2347634;C2348143;C2699239
0,sglt - nmbr inhibitors^,C0053917;C1334884;C3665045
0,severity of hypertensionb,C0439793;C0522510
0,severity n ( % ),C0439793;C0522510
0,severely impaired,C0205082
0,severe teaes,C0205082;C4050465;C4050466
0,severe n z nmbr,C0053917;C0205082;C1334884;C4050465;C4050466
0,severe impairment ( < nmbr ),C0053917;C0205082;C0221099;C0684336;C1334884;C4050465;C4050466
0,severe hyperkalemiac,C0205082;C4050465;C4050466
0,severe dysfunction,C3274777
0,serum uric acid ( mg / dl ),C0439269;C0455272;C0700634
0,serum total cholesterol  mmol / l ( sd ),C0587184;C1287371;C1532563;C2699239
0,serum sodium — meq / liter,C0439152;C0475211;C0523891
0,serum potassium — mmol / liter,C0302353;C0439190;C0475211;C0543465
0,serum hdl cholesterol ( mmol / l )  mean ( sd ),C0428472;C0444504;C1532563;C2347634;C2348143;C2699239
0,serum creatinine — pmol / liter,C0201976;C0439192;C0475211;C0600061
0,serum creatinine > nmbr pmol / l . n ( % ) |,C0053917;C0201976;C0439284;C0600061;C1334884
0,serum creatinine > nmbr mmol / l  n ( % ),C0053917;C0201976;C0600061;C1334884;C1532563
0,serum creatinine  mean ( sd )  pmol / l,C0201976;C0439284;C0444504;C0600061;C2347634;C2348143;C2699239
0,serum creatinine  limo nmbr nmbr,C0053917;C0201976;C0600061;C1334884
0,serum cholesterol — mmol / liter,C0439190;C0475211;C0587184
0,seropositivity,C0521143
0,serious ae,C0205404;C3887670
0,selected clinical characteristics  n ( % ),C0683325;C1707391
0,second prior mi,C0205436;C0332152;C0457385;C0565930;C1561503;C1705190;C2826257;C3810814
0,scr  gmol / l,C1539487;C4050416
0,score on nih stroke scale — median ( iqr ),C0449820;C0549183;C0876920;C1697238;C2347635;C2348144;C2939193;C3484372;C4050231
0,score on modified rankin scale — no . ( % ) §,C0449820;C2984908;C3854213;C4050231
0,score of > nmbr . nmbr — %,C0053917;C0449820;C1334884;C4050231
0,riva roxa ban n / n { % ) nmbr ( nmbr . nmbr ),C0053917;C0683610;C1334884;C4553947
0,risk of bleeding,C3251812
0,right ventriculardysfunction atinclusion,C0205090;C0444532
0,right coronary,C0225808
0,reversibility of fevnmbr ( % ),C0449261
0,reversibility ( bnmbr - agonist )  %  mean ( sd ) nmbr,C0053917;C0444504;C0449261;C1334884;C2347634;C2348143;C2699239;C2987634
0,revascularization,C0581603
0,responders of three - item end point at nmbr weeks *,C0205449;C1551338;C2349179;C2826544;C4554251
0,respiratory medication ( % ),C0418986
0,resection performed  %,C0015252;C0728940
0,repaired chd,C0205340;C0280604;C3542407
0,rentrop score,C0449820;C4050231
0,renin inhibitor ( e . g . aliskerin ),C1960108;C3537174;C4521920
0,remission  n ( % ),C0544452;C0687702
0,receiving concomitant nsaids and / or cox - nmbr inhibitors,C1514756
0,receiving concomitant corticosteroids,C1514756
0,received an oral aha within nmbr weeks prior to screening,C1514756
0,reason for enrollment in active a — no . ( % ),C0392360;C1516879;C1696073;C3888021
0,ratio of ldl to hdl,C0456603;C1547037
0,ratet ( nmbr % cl ),C0053917;C0596019;C1334884
0,rankin grade,C0441800;C0919553;C3244287
0,rando . in na * *,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
0,radial access,C0442038;C0444454;C0920847;C1554204
0,ra symptom duration — year,C0439234;C0439508;C0449238;C1457887;C2926735;C3538806;C3854129;C4048756
0,qualifying mi type,C0332307;C1514624;C1547052;C3810814
0,qualifying hbanmbrc ( % ),C1514624
0,qualifying event — no . ( % ),C0441471;C1514624;C4019010
0,psap - b ( ng / ml ),C0439275;C1418975;C1420002;C1425004
0,psa duration  years,C0439234;C0449238;C2926735;C3810537;C3813209
0,prior years taking warfarin,C0332152;C0439234;C2826257
0,prior tnfi  n ( % ),C0332152;C2826257
0,prior surgery : no,C0455610
0,prior pci or cabg surgery,C0332152;C2826257;C4049621
0,prior myocardial infarction,C0155668
0,prior ischemic stroke,C0332152;C0948008;C2826257
0,prior implantable cardiodefibrillator  n ( % ),C0021102;C0332152;C2826257
0,prior immunnosupressive failure but no anti - tnf failure,C0231174;C0332152;C0680095;C2826257
0,prior history of cardiovascular disease  n ( % ),C0332152;C0455539;C2826257
0,prior failure of anti - tnf therapy — no . ( % ),C0231174;C0281481;C0332152;C0680095;C2826257
0,prior coronary revascularization  n ( % ),C0332152;C0877341;C2826257
0,prior coronary revascularization,C0332152;C0877341;C2826257
0,prior cardiovascular event — no . ( % ) - j -,C0332152;C1320716;C2826257
0,prior cardiovascular event — no . ( % ),C0332152;C1320716;C2826257
0,prior biologic therapy ( including anti - tnfs ),C0278947
0,prior anti - tnf therapy — no . ( % ),C0281481;C0332152;C2826257
0,primary pci ( n = nmbr ),C0053917;C0205225;C0439612;C0439631;C1334884;C4049621
0,primary end point kaplan - meier rate  %,C0871208;C1521828;C2986535
0,primary end point  no . of events / total no . ( % ),C2986535
0,primary + gusto moderate or severe bleeding,C0205225;C0439612;C0439631
0,previous coronary revascularization — no . ( % ),C0205156;C0877341;C1552607
0,previous bowel resection performed — no . of patients ( % ),C0205156;C0741614;C1552607
0,presence of mets,C0150312;C0392148;C0812270;C1705694;C2939420;C3854307
0,presence of honeycombing  nmbr n ( % ),C0053917;C0150312;C0332468;C0349384;C0392148;C1334884;C3854307
0,presence of dactylitis  n ( % ),C0150312;C0239161;C0392148;C3854307
0,pre - bronchodilator fevnmbr ( % predicted normal ),C2599602
0,postmenopausal  never or past hormone therapy use,C0232970;C2003901
0,post - menopausal ( a ),C0232970
0,post - bronchodilator reversibility fevnmbr ( % ) mean ( sd ),C0444504;C0449261;C2347634;C2348143;C2599594;C2699239
0,post - bronchodilator ratio of fevnmbr to fvc — %,C0456603;C1547037;C2599594
0,post - bronchodilator fevnmbr ( % predicted * ),C2599594
0,positive for anti - cyclic citrullinated peptide antibody — no . ( % ) f,C0741132;C1320283
0,positive,C0439178;C1446409;C1514241;C2825490;C3812269
0,pooled simva,C1709595;C2349200;C4522255
0,pnmbrynmbr inhibitor,C1999216
0,planned treatment strategy,C0599880;C0679199
0,planned treatment duration  n ( % ),C4528394
0,pfo closure group ( n = nmbr ),C0053917;C0185003;C0441848;C1334884;C1521802
0,permanent,C0205355
0,peripheral vasodilators,C0724804
0,peripheral edema,C0085649
0,perianal or anus,C0442158
0,peri - or postmenopausal,C0347985
0,percentage with disease duration < nmbr years,C0053917;C0439165;C0439234;C0872146;C1334884;C1549488;C1561533
0,percentage difference ( nmbr % cl ),C0053917;C0439165;C0596019;C1334884;C1549488;C1561533;C1705241;C1705242
0,percent change,C0392747;C0439165;C0443172;C1705241;C4319952
0,pdenmbr inhibitor monotherapy,C1999216
0,patients ' characteristics age ( years )  mean + sd,C0444504;C0815172;C1510829;C2347634;C2348143;C2699239
0,patient ' s global assessment of disease activity  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C4054228
0,pathological q waves,C0429090
0,past or current angina pectoris,C1444637;C4284302
0,pasi score ! * *,C0449820;C4050231;C4528685
0,pasi score  mean ± sd,C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4528685
0,pasi < nmbr *,C0053917;C1334884;C4528685
0,partial mayo score $ | |,C0449820;C0454788;C0728938;C1077578;C1550516;C4050231
0,parameter,C0549193;C1704769;C2350001
0,pancolitis,C0868908
0,pain in extremity,C0030196;C4553007
0,pad lower extremities,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
0,p value versus placebo,C1709380
0,p value for adjusted hr,C0456081;C1709380
0,p  subgroup *,C0369773;C1079230;C1515021;C2603361
0,p  all vs all,C0369773;C2603361
0,outcome,C1274040
0,other oral hypoglycemic drug ( s ),C0359086
0,other countries,C0454664
0,other ( nmbr . nmbr % ) t,C0053917;C1334884
0,oral medications,C0304289
0,oral hypoglycemic drug,C0359086
0,oral hypoglycemic agent,C0359086
0,oral antidiabetes monotherapya  n ( % ),C0442027;C4521986
0,oral anticoagulant — no . / total no . ( % ),C0354604
0,oral aminosalicylates,C0368663;C0442027;C4521986
0,oral agents use,C0442027;C0450442;C1254351;C1521826;C4521986
0,opg  ( ng / ml ),C0439275;C1262886;C1336645;C1412836;C1710303
0,open triple ( n = nmbr ),C0175566
0,one or more requiring hospitalization in nmbr mo before screening — no . ( % ) nmbr,C0205447
0,one or more blood pressure medications  n ( % ),C0205447
0,o total randomized,C0439175;C0439810;C0483204
0,nyha class within past month — no . / total no . ( % ),C1882083;C4331910
0,nyha class nmbr - nmbr : no { n = llll ),C0053917;C1334884;C1882083
0,nyha class iii or iv ( n = nmbr ),C1882086
0,number of subjects,C0237753;C0449788;C0681850;C1550501;C1706203;C2349001;C2697811
0,number of prior csdmards  n ( % ),C0237753;C0332152;C0449788;C2826257
0,number of patients with,C2360800
0,number of pack - years,C0237753;C0449788;C1277691
0,number of exacerbations in last nmbr months ,C0237753;C0449788;C4086268
0,number ( % ) of patients with event,C2360800
0,ntpro - cnp ( ng / ml ),C0439275;C3889729
0,not reported in ecrf,C1518422
0,not reported / unknown,C1518422
0,non - stemi,C3537184
0,non - q wave,C0429089;C1305738;C1518422
0,non - metsyn,C1518422
0,non - hdl - c in nmbr classes,C0053917;C0456387;C1334884;C1518422;C1518526;C1705943;C3715113;C4019422
0,non - hdl - c ( mmol / l  mean ),C0444504;C1518422;C1532563;C2347634;C2348143;C3715113
0,non - hdl - c ( mg / dl ) - mean ± sd,C0439269;C0444504;C1518422;C2347634;C2348143;C2699239;C3715113
0,no prior ml or stroke,C0332152;C0439526;C1705224;C2826257;C3887665
0,no peripheral revascularization ( n = nmbr  nmbr ),C0053917;C0205100;C0581603;C1334884
0,no dysglycaemia or mets,C1960636
0,no . of prior tnfi,C0332152;C2826257
0,no . of prior bdmards,C0332152;C2826257
0,no . of nmbr - mg acetaminophen tablets / day,C0053917;C0439422;C1243102;C1334884
0,no . of days to homa - ir testing — median ( iqr ),C0439228
0,nmbrth - nmbrth percentiles,C1264641
0,nmbrnd > nmbr . nmbr / < nmbr . nmbr,C0053917;C1334884
0,nmbrmwd decrease > nmbr m,C0053917;C0369637;C0392756;C0441923;C0547047;C1334884
0,nmbrbaseline mean,C0444504;C2347634;C2348143
0,nmbr yr km % ( n ),C0053917;C0439234;C1334884;C3887676
0,nmbr year or more,C0053917;C0439234;C0439508;C1334884
0,nmbr to < nmbr . nmbr %,C0053917;C1334884
0,nmbr prolonged antithrombotic pretreatment ( n = nmbr ),C0053917;C1334884
0,nmbr no . of events,C0053917;C1334884
0,nmbr mg / kg ( n = nmbr ),C0053917;C0439272;C1334884
0,nmbr locf ),C0053917;C1334884;C2825507
0,nmbr degree of ica stenosis 丰,C0053917;C0201519;C1334884;C4034225
0,nmbr bmi  kg / m,C0053917;C0578022;C1334884;C1532718
0,nmbr = help needed  still independent,C0053917;C1334884
0,nmbr . nmbr - nmbr . nmbr ml / min / nmbr . nmbr mnmbr,C0053917;C0439445;C1334884
0,nmbr - nmbr / week,C0053917;C0332174;C0439230;C1334884
0,nmbr - nmbr ( severe ),C0053917;C1334884
0,nmbr - nmbr ( n = nmbr  nmbr ),C0053917;C1334884
0,nmbr - aminosalicylic compounds — no . ( % ),C0053917;C0205198;C1334884;C1706082
0,nmbr - aminosalicylates | | | |,C0053917;C0368663;C1334884
0,nmbr ( fevnmbr < nmbr % pred ),C0053917;C1334884
0,nmbr % < hbanmbrc < = nmbr %,C0053917;C1334884
0,nmbr  nmbr / nmbr  nmbr ( nmbr . nmbr ),C0053917;C1334884
0,never / rarely,C0522498;C2003901
0,negative,C0205160;C1513916;C2825415;C2825491;C3853545
0,native latin,C0302891
0,nace ( primary endpoint ),C2986535
0,n analysed,C0369718;C0441922
0,musculoskeletal,C0497254;C2707260
0,multivessel pci,C4049621
0,multiple tnfi *,C0439064
0,multiple,C0439064
0,months since ra was first diagnosed  mean ( sd ),C0439231
0,months from mi — median ( iqr ),C0439231;C0549183;C0876920;C2347635;C2348144;C2939193;C3810814
0,modmy al randcnxzaton,C0202311
0,modified rankin scale score,C0449820;C2984908;C3854213;C4050231
0,moderate teaes,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
0,moderate or severe exacerbations in the previous year ( range ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
0,moderate or less airflow limitation,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
0,moderate impairment ( nmbr to < nmbr ),C0053917;C0205081;C0221099;C0684336;C1334884;C1881878;C4049705;C4049706;C4085643;C4321335
0,ml without st - segment elevation !,C0439526;C0520886;C1705224;C3887665
0,missing — number / n ( % ),C0237753;C0449788;C1551393;C1705492;C3272743
0,missing data — no . / total no . ( % ),C4684714
0,missing data,C4684714
0,min  max,C0702093;C1524029;C3813700
0,mild or moderate copd,C2945599
0,mild impairment ( nmbr to < nmbr ),C0053917;C0221099;C0684336;C1334884;C2945599
0,microalbuminuria or proteinuria,C0730345
0,mi type unknown ( % ),C0332307;C1547052;C3810814
0,mi or cad,C3810814
0,mets w / o tnmbrdm,C0812270;C1705694;C2939420
0,mental component score ( mcs ),C0229992;C0449432;C0449820;C1705248;C4050231
0,menopausal status and use of hrt ( % ) y,C1513126
0,medically important infectionsa,C3898777;C4084912
0,medical therapy only ( n = nmbr ),C0053917;C0205171;C0418981;C1334884;C1720467
0,medical therapy ( n = nmbr ),C0053917;C0418981;C1334884
0,medical history — no . / total no . ( % ),C0262926;C1704706
0,medical history and risk factors — no . ( % ),C0262926;C1704706
0,medical history,C0262926;C1704706
0,medical characteristics,C0199168;C0205476;C1521970
0,median total cholesterol  mmol / l,C0201950;C0543421;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
0,median change  %,C0392747;C0443172;C0549183;C0876920;C1705241;C2347635;C2348144;C2939193;C4319952
0,median cardiac troponin t ( iqr ) — pg / ml,C0439297;C0549183;C0876920;C2347635;C2348144;C2939193;C3538889
0,median blood eosinophil count  cells per pla,C0200638;C0456170;C0549183;C0876920;C2347635;C2348144;C2939193
0,median ( sd )  mg / mmol,C0549183;C0567349;C0876920;C2347635;C2348144;C2348885;C2699239;C2939193
0,median ( qnmbr : qnmbr ) tgs,C0549183;C0876920;C1156212;C1537574;C2347635;C2348144;C2939193
0,median ( iqr ) age  years,C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
0,median ( days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
0,measurements,C0242485
0,measured at home with automated device,C0444706;C3541902
0,mean — mg / dl level — no . ( % ),C0439269;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2946261
0,mean — g / dl,C0439267;C0444504;C2347634;C2348143
0,mean yearly decline,C0444504;C2347634;C2348143
0,mean sgrq total score ( sd ),C0439175;C0439810;C0444504;C2347634;C2348143;C2699239;C2964552;C3533236
0,mean score on haq - di §,C3533236;C3826998;C4321476
0,mean score on dasnmbr - nmbr ( crp ) ^,C0053917;C1334884;C3533236;C3890735;C4048285
0,mean prebronchodilator fevnmbr ( sd )  % predicted,C0444504;C2347634;C2348143;C2599602;C2699239
0,mean number of exacerbations ( per patient - year [nmbr % ci] ),C0237753;C0444504;C0449788;C2347634;C2348143;C4086268
0,mean nmbrmwd *  m ( sd ),C0369637;C0441923;C0444504;C2347634;C2348143;C2699239
0,mean iglar dose ± sd ( u / day ),C0178602;C0444504;C0456683;C0869039;C1114758;C2347634;C2348143;C2699239
0,mean hscrp  mg / l ( sd ),C0439268;C0444504;C2347634;C2348143;C2699239
0,mean fevnmbr  l ( sd ),C0444504;C2347634;C2348143;C2699239
0,mean eosinophil count  per ml,C0200638;C0439526;C0444504;C0750879;C1705224;C2347634;C2348143;C3887665
0,mean duration of disease  years,C0439234;C0444504;C0872146;C2347634;C2348143
0,mean change in radiographic end points,C0392747;C0443172;C0444504;C0444708;C1705241;C2347634;C2348143;C2349179;C4319952
0,mean cdai score,C0444504;C0683448;C1413248;C2347634;C2348143;C3273706
0,mean bmi  kg / mnmbr ( s . d . ),C0444504;C0578022;C1275571;C2347634;C2348143
0,mean annualized exacerbation rate,C0444504;C0871208;C1521828;C2347634;C2348143;C4086268
0,mean age ( years ) race,C0444504;C1510829;C2347634;C2348143
0,mean age ( years ) ( s . d . ),C0444504;C1510829;C2347634;C2348143
0,mean age  y  median ( range ),C0001779;C0444504;C0549183;C0876920;C1514721;C2347634;C2347635;C2348143;C2348144;C2348147;C2939193;C3542016
0,mean a ± sem ( % ),C0444504;C2347634;C2348143
0,mean a ± sd ( mmhg ),C0444504;C2347634;C2348143
0,mean ( sd ) swollen joint count *,C0444504;C0451521;C2347634;C2348143;C2699239
0,mean ( sd ) post - bronchodilator fevnmbr reversibility  %,C0444504;C0449261;C2347634;C2348143;C2599594;C2699239
0,mean ( sd ) extent of exposure  days,C0274281;C0332157;C0439228;C0439792;C0444504;C2347634;C2348143;C2699239
0,mean ( sd ) dasnmbr - nmbr ( esr ) *,C0053917;C0444504;C1334884;C2347634;C2348143;C2699239;C3811131
0,mean ( sd ) crp  mg / l *,C0439268;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
0,mean ( s . d . ) hbalc  %,C0444504;C2347634;C2348143
0,mean ( s . d . ) free pcsknmbr  ng / ml,C0332296;C0439275;C0444504;C1880497;C1996904;C2347634;C2348143
0,mases ( nmbr - nmbr )  mean ( sd ),C0053917;C0444504;C1334884;C2347634;C2348143;C2699239
0,managed medically — no . / total no . ( % ),C1273870
0,major cerebrovascular,C0205082;C0205164;C1880018;C4318856;C4521762
0,lvef ( % )  mean ± sd,C0428772;C0444504;C0488728;C2347634;C2348143;C2699239
0,lvdd ( mm ),C4330985;C4554674
0,low risk and fewer symptoms ( group a ),C3272281;C3538919
0,low hdl cholesterol,C0151691
0,loop at last follow - up,C0445022;C0589120;C1522577;C1704685;C3274571
0,location of ml,C0439526;C0450429;C1515974;C1705224;C3887665;C4284930;C4284931
0,lm bifurcation not treated,C0184906;C1261082;C1551056;C3146289
0,lipid levels — mg / dl,C0428460;C0439269
0,lipid - lowering therapy,C0585943
0,level nmbr immobility § | |,C0053917;C0231441;C0441889;C0456079;C1334884;C1547707;C2946261
0,less than nmbr %,C0053917;C0439092;C1334884
0,lesions bnmbr / c,C0221198
0,lesion length  mean ( sd )  mm,C0221198;C0444504;C1444754;C1546698;C1706316;C2347634;C2348143;C2699239;C4330985;C4554674
0,left circumflex artery,C0226037
0,left circumflex,C0205091;C0443246;C1552822;C1880089
0,left anterior descending artery  n ( % ),C0226032
0,left anterior descending  n ( % ),C0205386;C0441998;C1547177
0,left anterior descending,C0205386;C0441998;C1547177
0,ldl particle size ( week nmbr ),C0053917;C0332174;C0439230;C1334884;C3641256
0,ldl - cihdl - c  mean ( sd ),C0444504;C2347634;C2348143;C2699239
0,ldl - c < nmbr . nmbr mmol / l,C0053917;C1334884;C1532563
0,ldl - c ( bq ) ( mg / dl ) - mean ± sd,C0439269;C0444504;C0560038;C2346983;C2347634;C2348143;C2699239;C3541236;C3642216
0,large mi,C0549177;C3810814
0,laboratory measurements,C0681902
0,laboratory findings,C0587081
0,laba users,C1706077
0,laba / lama,C0999593;C1416775
0,kim nmbr ( pg / ml ),C0053917;C0439297;C1334884
0,killip class at admission — no . / total no . ( % ),C0184666;C0809949;C1881332
0,killip class,C1881332
0,jsn score  mean nmbr sd,C0053917;C0444504;C0449820;C1334884;C2347634;C2348143;C2699239;C4050231
0,joint swelling,C0152031
0,iwqol - lite physical score ( arbitrary units ),C0439183;C4483112
0,isolated systolic hypertension  n ( % ) “,C0745133
0,isolated igt,C0205409;C1548221
0,ischemic tvr,C0475224
0,ischaemic  n ( % ),C0475224
0,invasive,C0205281;C1334278
0,intravenous vasodilators ( % ),C0443081
0,intraperitoneal,C0442120
0,intervention in complex lesions,C0221198;C1292781
0,interval pain onset to admission,C0184666;C0809949;C1272706;C1507009;C1552654;C1552713
0,intermediate ( nmbr ) ( n = nmbr  nmbr  nmbr % ),C0053917;C0205103;C1334884;C1550465;C2827755;C3889971
0,interaction : treatment by psoriasis p valuenmbr,C1704675;C3258078
0,int . p *,C3272375
0,inflammatory disease,C1290884
0,indication for pci,C0392360;C3146298;C4049621
0,indian ( indian subcontinent ),C0454693
0,indeterminate or unknown,C0205258
0,ind / glynmbr / nmbr pg o . d . n = nmbr,C0053917;C1334884;C2827928;C4049864
0,incidence rate,C1708485
0,impaired fasting glucose level ( n = nmbr ),C0053917;C0202045;C0221099;C0441889;C0456079;C1272092;C1334884;C1547707;C2946261
0,hormone therapy,C0279025
0,hormonal status,C0449438;C0458083
0,homa . % b  median ( ql  qnmbr )  %,C0549183;C0876920;C2347635;C2348144;C2939193
0,hoehn and yahr stage ( range  nmbr - nmbr ),C0053917;C0205390;C1300072;C1306673;C1334884;C1514721;C2348147;C3542016
0,history of systemic hypertension,C0205373;C0455527
0,history of peripheral vascular disease,C1881056
0,history of peripheral artery disease,C0489868;C0683519;C0730226;C0850708;C0944983
0,history of percutaneous coronary intervention,C1320647;C4554713
0,history of paroxysmal atrial fibrillation  n ( % ),C0205311;C0729790
0,history of myocardial infarction ( % ),C1275835
0,history of microvascular disease — no . ( % ),C0443258;C0683519;C0730226;C0850708;C0944983
0,history of intermittent claudication and abi < nmbr - nmbr or substantial peripheral arterial stenosis > nmbr %,C0205267;C2315493
0,history of hyperlipidemia ( % ),C4695788
0,history of hypercholesterolemia  n ( % ),C1533076
0,history of hypercholesterolemia,C1533076
0,history of currently treated hypertension  n ( % ),C0455527;C0521116;C1522326
0,history of congestive heart failure,C0455531;C0742742
0,history of cardiovascular disease — no . ( % ) ^ |,C0455539
0,history of cardiovascular disease,C0455539
0,history of cardiac arrhythmia,C3494593
0,history of alcohol use,C0551571;C0552479
0,highest tg tertile,C0337445;C1522410
0,high subgroup,C0205250;C1079230;C1299351;C1515021;C2700149;C3887512;C3889660;C4321237;C4522209
0,high potencyc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
0,high intensity,C4081854
0,high ( > nmbr ) ( n = nmbr  nmbr  nmbr % ),C0053917;C0205250;C1299351;C1334884;C2700149;C3887512;C3889660;C4321237;C4522209
0,hfpef ( ef n nmbr )  ( % ),C0053917;C1334884
0,hemoglobin  g nmbr nmbr,C0053917;C1319312;C1334884
0,heart disease risk factors,C0741920
0,health habits,C0679786
0,hbanmbrca  % ( mmol / mol ),C3829066
0,hbanmbrc nmbr - < = nmbr %,C0053917;C1334884
0,hbanmbrc nmbr % - < nmbr % ( n - nmbr ),C0053917;C1334884
0,hbanmbrc category  n ( % ),C0683312;C3889287
0,hbanmbrc  mean ( sd )  % [mmol / mol],C0444504;C2347634;C2348143;C2699239;C3829066
0,hbalc > = nmbr % ( n - nmbr ),C0053917;C1334884
0,hazard ratio ( nmbr % cl ) nmbr . nmbr ( nmbr . nmbr  nmbr . nmbr ),C0053917;C0596019;C1334884;C2985465
0,haq - di score ( nmbr - nmbr ),C0053917;C0449820;C1334884;C3826998;C4050231;C4321476
0,haemorrhagic,C0333275
0,glucose test,C0337438;C0595310
0,genotyping,C1285573
0,general and lumbar epidural,C0205246;C3812897;C3891294;C4521767
0,gad positive — no . ( % ) ^,C0270549;C0439178;C1414925;C1446409;C1514241;C2825490;C3812269
0,fpg ( mmol / l )  mean ( sd ) 、,C0444504;C1532563;C2347634;C2348143;C2699239
0,fpg  mean ( sd )  mmol / l,C0444504;C1532563;C2347634;C2348143;C2699239
0,former smoker ( n = nmbr ),C0053917;C0337671;C1334884
0,former smoker  n ( % ),C0337671
0,former or never,C0205156;C0750523
0,former n z nmbr,C0053917;C0205156;C0750523;C1334884
0,formal education  years,C0439234;C0681344
0,final timi flow grade post - ppci,C0205088;C0441800;C0687676;C0919553;C1546485;C1704687;C3244287;C3272266;C3469826;C3853528
0,final timi flow,C0205088;C1546485;C3272266;C3853528
0,fevnmbr percent predicted ( sd ),C0439165
0,fevnmbr % reversibility,C0449261
0,fevi  l *,C0429706;C0849974;C1561566;C4528367
0,fevi  % predicted  mean ( sd ) nmbr,C0849974;C1561566;C4528367
0,fc - ldl - c  mg / dl,C0439269;C2983605
0,fc - ldl - c  friedewald - calculated,C2983605
0,fatal and nonfatal stroke,C1302234;C1705232
0,fatal and nonfatal ml,C1302234;C1705232
0,fasting blood glucose ( mg / dl ),C0428568;C0439269;C1261430
0,family history ol diabetes ?,C1313937
0,family history of diabetes — no . ( % ),C1313937
0,family history of coronary artery disease,C2317524
0,factor xa inhibitor,C2825027;C4553708
0,extent of disease  n ( % ),C0449279;C4553144
0,extent of disease  %,C0449279;C4553144
0,extensive,C0205231
0,exposure,C0274281;C0332157
0,exacerbations in the previous year,C0205156;C0439234;C0439508;C1552607;C4086268
0,exacerbations,C4086268
0,evomab ( n = nmbr ),C0053917;C1334884
0,events  no .,C0441471;C3541888
0,event rates  %,C0441471;C0871208;C1521828;C4019010
0,event / total,C0439175;C0439810;C0441471;C4019010
0,evenls per nmbr  nmbr palienl - years,C0053917;C0439234;C1334884
0,evaluable for acrnmbr at week nmbr  n,C1516986
0,estimated glomerular filtration rate - ml / min  median ( iqr ) ',C0439445;C0549183;C0876920;C2347635;C2348144;C2939193;C3811844
0,estimated glomerular filtration rate ( mdrd )  ml / min / nmbr . nmbrmnmbr,C0053917;C0439445;C1334884;C3811844;C3839656
0,estimated glomerular filtration rate,C3811844
0,estimated glomerular filtration,C0232809;C0750572
0,estimated creatinine clearance < nmbr ml / min *,C0053917;C0439445;C0750572;C0812399;C1334884
0,estimated * creatinine clearance < nmbr mlvmin  %,C0053917;C0750572;C0812399;C1334884
0,established ascvd or > nmbr cv risk factors,C0443211;C1272684;C3665365
0,established ascvd,C0443211;C1272684;C3665365
0,established,C0443211;C1272684
0,erosion score  median ( min  max ),C0333307;C0449820;C0549183;C0702093;C0876920;C1524029;C1880549;C1959609;C2347635;C2348144;C2939193;C3813700;C3887524;C4050231
0,erosion score,C0333307;C0449820;C1880549;C1959609;C3887524;C4050231
0,enthesitis count,C0750480;C1282952;C1705566
0,endovascular — no . ( % ),C0524425
0,emotional well - being,C2984554;C3641833
0,emergent / urgent surgery,C0750573;C2188405
0,elevated tg,C0205250;C0337445;C3163633
0,elevated hscrp > nmbr mg / l  n ( % ),C0053917;C0205250;C0439268;C1334884;C3163633
0,elevated creatinine ( > nmbr pmol / l ),C0053917;C0151578;C0439284;C0700225;C1334884
0,elevated at wk nmbr — no . ( % ) nmbr,C0053917;C0205250;C0332174;C0439230;C1334884;C3163633
0,electrophysiological study — no . ( % ) weight — ibj,C0850293
0,ejection fraction  % nyha class  n ( % ),C0489482;C1882083;C2700378
0,egfrmdrd < nmbr ml - min - nmbr - nmbr . nmbr m - nmbr  n ( % ),C0053917;C0369637;C0439445;C0441923;C1334884
0,efficacy and safety : net adverse clinical events *,C1280519;C1707887
0,efficacy,C1280519;C1707887
0,education  high school or higher,C0683862
0,dx at presentation  n ( % ),C0449450;C3538936
0,duration of tnmbrdm ( % ),C0449238;C2926735
0,duration of tnmbrdm  y,C0449238;C2926735
0,duration of tnmbrdm,C0449238;C2926735
0,duration of study - drug infusion,C0392877;C0449238;C0557651;C2603343;C2926735
0,duration of ra ( years ),C0439234;C0449238;C2926735;C3538806;C4048756
0,duration of morning,C0332170;C0449238;C2926735
0,duration of infusion — hr,C0449238;C0574032;C1827465;C2926735
0,duration of disease  years,C0439234;C0872146
0,duration of disease  median,C0549183;C0872146;C0876920;C2347635;C2348144;C2939193
0,duration  mean ( sd )  years,C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
0,dual antiplatelet,C0205173;C1554184
0,dpi ( other than diskus )  n,C1553480
0,dose of aspirin,C4696290
0,dlqi  nmbr - nmbr *,C0053917;C1334884;C3899393
0,distal anastomosis ( % ),C0448964
0,diskus only  n,C0205171;C1553480;C1720467
0,disease location / type : terminal ileum,C0227327;C0450429;C0457464;C1515974;C4284930;C4284931
0,disease duration nmbr to bnmbr years ( n = nmbr ),C0053917;C0439234;C0872146;C1334884
0,disease duration  median ( range ) years,C0439234;C0549183;C0872146;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
0,discontinuations teaes,C0457454
0,discontinuations,C0457454
0,difference vs placebo  % [nmbr % cl]  p,C1705241;C1705242
0,difference from baselinea,C1705241;C1705242
0,difference ( a ) vs placebo ( nmbr % cl ),C1705241;C1705242
0,diabetes therapy  n ( % ),C3274787;C3539002
0,diabetes mellitus status,C1317301
0,device group,C1706365
0,demographic characteristics,C0683970
0,decreased appetite,C0232462
0,days of study - drug administration ( % ) * * nmbr day,C0053917;C0150270;C1334884;C2826182;C3469597
0,data missing or no drug given,C1511726;C1551393;C1705492;C3245479;C3272743;C3714741
0,data missing,C1511726;C3245479;C3714741
0,dasnmbr - esr lda,C3811131;C4553195
0,dasnmbr ( esr )  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3811131
0,dactylitis count ( nmbr - nmbr )  mean ( sd ),C0053917;C0239161;C0444504;C0750480;C1334884;C1705566;C2347634;C2348143;C2699239
0,dactylitis count,C0239161;C0750480;C1705566
0,dactylitis  n ( % ),C0239161
0,current smoker — no . of patients ( % ),C3173209;C3241966
0,current smoker : ex - smoker ( % ),C3173209;C3241966
0,current or previous atrial fibrillation,C0521116;C1705970
0,current medication — no . ( % ),C0746467
0,current drinker,C0556297
0,current / past,C0521116;C1444637;C1705970;C4284302
0,csf nmbrs - hydroxy -,C0053917;C1334884;C3540512;C3889436
0,crp ( mg / l ) : < nmbr,C0053917;C0439268;C1334884;C3890735;C4048285
0,crp ( mg / l )  median ( min  max ),C0439268;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700;C3890735;C4048285
0,crp ( mg / dl ) < nmbr . nmbr,C0053917;C0439269;C1334884;C3890735;C4048285
0,crp  nmol / l  median ( range ),C0439282;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3890735;C4048285
0,crp  mg / l : median ( range ),C0439268;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3890735;C4048285
0,crohn ' s disease activity index score],C0449820;C0451071;C4050231
0,creatinine clearance ， : : nmbr ml / min  %,C0053917;C0439445;C0812399;C1334884
0,creatinine clearance by c - g ( ml / min ),C0151280;C0439267
0,creatinine clearance at admission ( ml / min ),C0151280;C0184666;C0809949
0,crcb - ( ml / min )  mean ( s . e . ),C0439390;C0439445;C0444504;C0702093;C1524029;C2347634;C2348143;C3813700
0,coronary bypass graft,C1260596
0,conventional treatment ( n = nmbr ),C0053917;C1334884;C2945704
0,conventional treatment,C2945704
0,concomitant therapy  no . ( % ),C1707479
0,concomitant therapy,C1707479
0,concomitant lipid - lowering therapy  n ( % ),C0521115;C0585943
0,concomitant corticosteroid use  n ( % ),C0239126;C0521115
0,combined n = nmbr,C0053917;C0205195;C1334884
0,combined estimated gfr and albuminuria status,C0205195
0,combined end points,C0205195;C2349179
0,cognitive functioning,C0392334;C0392335
0,coexisting conditions,C0679225
0,clinical presentation,C2708283
0,clinical criterianmbr,C0205210
0,clinical and laboratory measurements,C0205210
0,class l / ll heart failure,C0456387;C1518526;C1705943
0,class i or iii aad use in nmbr months before enrollment,C0441885;C1319793;C2698967
0,circumflex,C1880089
0,chd risk equivalents  n ( % ),C0439185;C1282512;C4049980
0,chd eze / simva ( n = nmbr],C0053917;C0280604;C1334884;C3542407
0,chanmbrdsnmbr - vasc score ( median  iqr ),C0449820;C0549183;C0876920;C2347635;C2348144;C2939193;C4050231
0,change in mtss ( mean ),C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
0,change in haq - di ( mean ) t,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3826998;C4319952;C4321476
0,ccv history / condition,C0683519
0,carotid revascularization,C0581603;C0741968
0,carotid,C0741968
0,cardiovascular risk factors — no . / total no . ( % ),C0850624
0,cardiovascular history 一 no . ( % ),C1880008
0,cardiovascular history — no . / total no . ( % ),C1880008
0,cardiovascular history,C1880008
0,cardiac therapy  n ( % ) d,C3654025
0,cardiac rhythm,C0232187
0,calculated ldl - c in nmbr classes,C0053917;C0444686;C0456387;C1334884;C1441506;C1518526;C1705943;C4019422
0,bypass surgery,C1536078
0,bsa > nmbr %  n ( % ) t,C0053917;C1334884
0,bolus administered — no . ( % ),C1186706;C1511237;C1705509;C3812160
0,bmi kg - m - nmbr,C0053917;C0578022;C1334884;C1532718
0,bmi ( nmbr . nmbr  nmbr . nmbr ),C0053917;C0578022;C1334884
0,blood eosinophil count ( nmbr cells per l ),C0053917;C0200638;C1334884
0,biomarker status,C0449442
0,bilateral disease ( % ) ' j ' ' j ',C1511113
0,before bronchodilation,C1371299;C3537072
0,basmi ( linear )  mean ( sd ),C0205132;C0444504;C2347634;C2348143;C2699239
0,baseline dyspnea index  mean total score,C0439175;C0439810;C0444504;C1511069;C2347634;C2348143;C2964552;C3533236
0,basal insulin dose at run - in ( u / day ),C0178602;C0205112;C0366513;C0456683;C0650607;C0869039;C1114758;C3274438
0,basal insulin analogue : insulin,C0205112;C0243071;C0650607;C2825028
0,bare metal stent  n ( % ),C2825200
0,bare - metal stent — no . ( % ),C2825200
0,atrial fibrillation / flutter  n ( % ),C0155709
0,atrial fibrillation / atrial flutter  %,C0155709
0,at least nmbr severe flare,C0053917;C0205082;C1334884;C1517205;C3540542;C4050465;C4050466
0,at least nmbr flare,C0053917;C1334884;C1517205;C3540542
0,aspirin at any dose,C4696290
0,ascvd including tia,C3665365
0,arb at last follow - up,C0589120;C1522577;C1704685;C3274571;C3888198
0,arb at enrollment,C1516879;C1696073;C3888021;C3888198
0,apolipoproiein anmbr ( tng / nmbr ),C0053917;C1334884
0,apo anmbr ( g / l ),C0439294;C0456615
0,anyantianginal agent,C0450442;C1254351;C1521826
0,any type  according to daily dose * *,C0332307;C0680240;C1547052;C2348070
0,any event,C0441471;C4019010
0,any dose reduction,C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
0,any aes  n ( % ),C1412268;C2699274
0,anticyclic citrullinated peptide positive^  n ( % ),C0439178;C1320283;C1446409;C1514241;C2825490;C3812269
0,anticoagulant therapy,C0150457
0,anmbr + eznmbr anmbr ( n = nmbr ) ( n = nmbr ),C0053917;C1334884
0,anmbr + ezio anmbr ( n = nmbr ) ( n = nmbr ),C0053917;C1334884
0,angina class iii or iv prior myocardial infarction,C0264677
0,anatomic complexity characteristics,C0439855;C0502371;C1704241
0,alt and / or ast > nmbr times uln consecutive #,C1266129;C4553172
0,alt  ast  or both > nmbrx uln,C3831581
0,allhat - llt,C2347090
0,all completers ( n nmbr nmbr ),C0053917;C1334884
0,age when diabetes first diagnosed — yr,C0001779
0,age at diagnosis  y,C1828181;C3173302
0,age [years] ( interaction : p = nmbr . nmbr ),C0053917;C1334884;C1510829;C1704675
0,age < nmbr years — no . ( % ),C0053917;C1334884;C1510829
0,age ( yrs ) < nmbr,C0001779;C0053917;C1334884
0,age ( years ) [median ( nmbrth to nmbrth percentile ) ],C0549183;C0876920;C1264641;C1510829;C2347635;C2348144;C2939193
0,age ( years ) : nmbr - < nmbr,C0053917;C1334884;C1510829
0,age  yrs  median ( nmbrth  nmbrth ),C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
0,age  mean years  [sd],C0444504;C1510829;C2347634;C2348143;C2699239
0,after pci,C4049621
0,after bronchodilation,C1371299;C3537072
0,adverse outcome,C1274040
0,additional investigations,C2359834
0,ada ifg,C1060325;C1334085;C1708411;C3811629
0,acute stent thrombosis,C0205178;C3897493
0,acute coronary event,C0205178;C0741923
0,acute and delayed reaction,C0205178
0,active or previous cancer,C0205177;C3853793;C3888249
0,active a,C0205177;C3853793;C3888249
0,acr  mg / mmol,C0567349;C1412134;C1515941;C2348885
0,acpa positive  %,C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
0,acc / aha lesion class bnmbr or c  n ( % ),C0221198;C0456387;C1518526;C1546698;C1705943;C4072694
0,abx - facil . pci,C4049621
0,absolute  litres,C0205344;C0475211
0,a / v ( n = nmbr ),C0053917;C1272460;C1334884
0,> nmbrmg / dl chd status,C0280604;C0449438;C3542407;C3642216
0,> nmbr vessels with > nmbr % stenosis,C0053917;C0679403;C1334884
0,> nmbr servings / wk ( n = nmbr ),C0053917;C0332174;C0439230;C1334884;C1519269
0,> nmbr oral agents,C0053917;C0442027;C0450442;C1254351;C1334884;C1521826;C4521986
0,> nmbr : obese class iii,C0053917;C1319441;C1334884
0,> nmbr . nmbrmmol / l ( n = nmbr ),C0053917;C1334884
0,< nmbr years eze / simva,C0053917;C0439234;C1334884
0,< nmbr months  n ( % ),C0053917;C0439231;C1334884
0,< nmbr ml / min / nmbr . nmbr mnmbr — no . ( % ),C0053917;C0439445;C1334884
0,< nmbr . nmbr mmol / liter triglyceride level,C0053917;C0428475;C0439190;C0475211;C1334884
0,( nmbr % ell ' ll  * non - hdl - c,C0053917;C1334884;C1427925;C3273466
0,( nmbr % cl ) interaction,C0053917;C0596019;C1334884;C1704675
0,( % ) nmbr - nmbr,C0053917;C1334884
0,( %  nmbr % cl ),C0053917;C0596019;C1334884
0,( $ nmbr mg / dl [nmbr . nmbr mmol / l] ),C0053917;C0439269;C1334884;C1532563
0,% predicted pre - bronchodilator fevnmbr  % *,C0681842;C1882327;C2599602
-1,zotarolimus - eluting,C1700035
-1,yes  insulin - treated,C0021641;C1533581;C1549445;C1579433;C1705108;C1710701;C3714501
-1,worsening angina,C0002965
-1,wml load at follow - up mri,C0024485;C0589120;C1522577;C1550025;C1704685;C1704782;C1708715;C1824234;C3274571;C3890166
-1,without insulin or insulin - modifying therapy,C0021641;C1533581;C1579433;C3714501
-1,without dm ( n = nmbrinmbr * ),C0011816;C3250443
-1,white : black : other,C0005680;C0007457;C0027567;C0043157;C0085756;C0220938;C0439541
-1,western european includinq australia  israel  and south africa,C0004340;C0022271;C0043128;C0239307;C0239312;C1535514
-1,western europe hr ( nmbr % cl ),C0043129;C0053917;C0596019;C1334884
-1,western europe and other,C0043129
-1,western europe and israel,C0043129
-1,western europe / australia / israel,C0004340;C0015176;C0022271;C0043128;C0043129
-1,weight ( kg / mnmbr ) [median ( nmbrth to nmbrth percentile ) ],C0022718;C0439209;C0549183;C0552346;C0876920;C2347635;C2348144;C2939193;C4054209
-1,weight $ nmbr . nmbr kg  < nmbr . nmbr kg  n,C0005910;C0043100;C0053917;C1305866;C1319635;C1334884;C1705104
-1,weight  median ( nmbrth — nmbrth percentiles )  kg,C0022718;C0439209;C0549183;C0552346;C0876920;C2347635;C2348144;C2939193;C4054209
-1,week nmbr ( itt population ),C0032659;C0053917;C0332174;C0439230;C1257890;C1334884
-1,week nmbr ( geometric mean  cv ),C0053917;C0332174;C0439230;C1334884;C2986759;C3538987;C4048877;C4318503
-1,vomiting,C0042963;C1963281;C3898969;C4084766;C4084767;C4084768;C4084769
-1,vitamin e,C0042874;C3714803
-1,very high risk,C0035647;C0332167;C0442804;C0442824;C2984081;C3272283;C4050568;C4319571;C4321397;C4552904
-1,vertebrobasilar infarct,C0021308;C0545733
-1,vents / patients,C0030705
-1,venous graft,C0042449;C0181074;C0332835;C0348013;C1961139
-1,vascular intervention,C0005847;C0184661;C0886296;C1273869;C1558950;C1801960
-1,vascular disordersb,C0005847;C1558950;C1801960
-1,vascular disease indicator no ( n = nmbr ),C0021212;C0042373;C1235732;C1522602
-1,varespladib ( n = nmbr ),C0053917;C1334884;C2713485
-1,v alsartan / hctz  n ( % ),C0020261
-1,use of parenteral antithrombotic,C0030547;C1524063;C4522267
-1,use of ics,C0815320;C1524063;C4551720
-1,use of hormone replacement therapy ( a ),C0282402;C1524063
-1,use of concomitant lipid - modifying therapy,C0023779;C0392747;C1524063;C1707479
-1,use of ace inhibitor,C0003015;C1524063;C4541021
-1,use nmbr - asa compounds,C0004057;C0042153;C0053917;C0205198;C0457083;C1334884;C1706082;C1947944;C3853627
-1,usa and canada,C0041703
-1,uric acid ( mg / dl ),C0041980;C0439269
-1,upper respiratory tract infection nmbr ( nmbr . nmbr ),C0041912;C0053917;C1334884
-1,upper gastrointestinal,C3203348
-1,unstable angina ( biomarker negative ),C0002965;C0005516;C0205160;C1513916;C2825415;C2825491;C3853545
-1,united states,C0041703
-1,unfractionated heparin before randomisation,C0019134;C0034656;C2825026
-1,type of des,C0011702;C0332307;C1547052;C4551552
-1,type of concomitant statin,C0332307;C0360714;C0521115;C1547052
-1,troponin t,C0077404;C1420827
-1,triple therapy use at screening  n ( % ),C0039798;C0042153;C0087111;C0457083;C1363945;C1947944;C2121434
-1,triglycerides — mmol / liter,C0041004;C0439190;C0475211
-1,triglycerides mean ( mg / dl ± sd ),C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
-1,triglycerides  median ( range ),C0041004;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
-1,treatmentofpulmonary embolismpriorto randomization,C0034656
-1,treatment with candesartan,C0039798;C0087111;C0717550;C1522326;C1533734;C1705169;C3538994;C3887704
-1,treatment at randomization — no . ( % ),C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
-1,treated with cabg — no . / total no . ( % ),C0010055;C0332293
-1,treated hypertension :,C0020538;C1522326;C1963138
-1,traditional chinese medicine for respiratory disease — no . ( % ),C0025124;C0035204;C0035242;C1515884
-1,total updrs score ( range  nmbr - nmbr ) 卞,C0439175;C0439810;C3639721
-1,total stent length,C0038257;C0439175;C0439810;C1444754;C1706316
-1,total score on the sgrq - c  i ,C0021966;C0221138;C2964552;C3826872
-1,total haq  nmbr - nmbr,C0053917;C0102923;C0439175;C0439810;C0451208;C1334884
-1,total comparators  patients with events / total patients,C0030705;C0439175;C0439810;C0441471;C1707454;C3541888;C4553389;C4553390
-1,tolal choleslerol - lo - hdl choleslerol ralio,C0206579;C1232424;C3715113
-1,tocilizumab ( n = nmbr ),C0053917;C1334884;C1609165
-1,tocilizumab,C1609165
-1,tobacco use ( % ),C0040335;C0543414;C0841002;C3853727
-1,toast classification of qualifying stroke,C0038454;C1514624;C1710306;C4521230;C4554100
-1,tirofiban ( n = nmbr ),C0053917;C0247025;C1334884
-1,tiotropium nmbr gg qd,C0017454;C0018370;C0053917;C0213771;C0332173;C1334884
-1,timing of clopidogrel loading dose,C0070166;C0449243;C1704250;C3714444
-1,timi risk score — no . ( % ) : t,C0035647;C0449820;C4050231;C4552904
-1,timi risk score nmbr - nmbr,C0035647;C0053917;C0449820;C1334884;C4050231;C4552904
-1,timi major bleeding,C0019080;C0205082;C0205164;C4318856;C4521762
-1,time since diagnosis of type nmbr diabetes,C0040223;C3541383
-1,time since diagnosis of osteoarthritis — yr,C0040223;C3541383
-1,time since diagnosis of diabetesa  n ( % ),C0040223;C3541383
-1,time of qualifying ecg to balloon inflation ( hrs ),C0040223;C1514624;C1623258;C3541383
-1,time from symptoms to treatment,C0040223;C0683368;C1457887;C3541383
-1,time from symptom onset to randomization,C0040223;C0449244;C1457887;C3541383;C3854129;C4086878
-1,time from randomization to pci ( st - elevation mi )  min,C0034656;C0040223;C3541383
-1,time from qualifying event to randomization,C0040223;C0441471;C1514624;C3541383;C4019010
-1,time from onset of pain to randomization  median ( iqr )  h,C0030193;C0449244;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
-1,time from acs to randomization ( median  iqr ),C0040223;C0742343;C3541383;C4318612
-1,tim nmbr nsk score,C0053917;C0449820;C1313407;C1334884;C3541335;C3711667;C3827754;C3890185;C4050231;C4319633
-1,ticlopidine ( n = nmbr ),C0040207;C0053917;C1334884
-1,thrombophilia,C0398623
-1,thrombolytic treatment before randomization,C0016018;C0034656;C0039798;C0087111;C0520997;C1522326;C1533734;C1705169;C3538994;C3887704
-1,thrombocytopenia,C0040034;C0392386
-1,three arm,C0205449;C0446516;C3715044;C4553528
-1,thoracic cage fractures,C0222762
-1,thienopyridine drug at start of open - label period,C0439531;C1120149;C1709323;C1948053;C2348346
-1,therapy at discharge,C0012621;C0030685;C0039798;C0087111;C1363945;C2926602
-1,theophylline compound,C0039771;C0205198;C1706082
-1,terol  hdl - c  high - density lipoprotein cholesterol ,C0023822
-1,tendonitis,C0039503
-1,temporary discontinuation of study drug,C0013175;C0205374;C0457454;C1444662;C1548539;C3245481;C4552847
-1,telmisartan ( n = nmbr  nmbr ),C0053917;C0248719;C1334884
-1,systolic blood pressure [mmhg] ( interaction : p = nmbr . nmbr ),C0053917;C0439475;C0488055;C0871470;C1306620;C1334884;C1704675
-1,systemic glucocorticoid use at randomisation,C0017710;C0034656;C0042153;C0205373;C0457083;C1947944
-1,systemic corticosteroid use,C0042153;C0205373;C0239126;C0457083;C1947944;C4053960
-1,syncope — no . ( % ),C0039070;C3541349;C4554644
-1,supine after nmbr minutes change from baseline,C0038846;C0053917;C0439232;C0700321;C0702093;C1282918;C1334884;C2347166
-1,subset of patients on metformin,C0030705;C1515021
-1,subarachnoid hemorrhage,C0038525
-1,study medication — no . ( % ),C0013227;C0557651;C2603343;C3244316;C4284232
-1,stroke or tia — no . ( % ),C0038454;C4554100
-1,stroke or pvd  ( % ),C0038454;C4554100
-1,stroke ( vs tia ),C0038454;C4554100
-1,stool frequency subscore,C0015733;C0183622;C0376249;C0439603;C0871396;C1561548;C1705502;C3898838;C4321352
-1,steroids § §,C0038317
-1,steroid use at baseline  n ( % ),C0168634;C0281991;C1442488
-1,steroid use at baseline,C0168634;C0281991;C1442488
-1,stent plus placebo,C0032042;C0038257;C0332287;C1696465;C1706408
-1,stent length per lesion  mm,C0038257;C0221198;C1444754;C1546698;C1706316;C4330985;C4554674
-1,statin with niacin,C0027996;C0360714;C1142562
-1,statin use at baseline,C0042153;C0168634;C0360714;C0457083;C1442488;C1947944
-1,statin treatment,C0039798;C0087111;C0360714;C1522326;C1533734;C1705169;C3538994;C3887704
-1,statin potency stratum  n ( % ),C0360714;C3245505
-1,statin monotherapy,C0360714
-1,statin + ezetimibe  n ( % ),C0360714;C1142985
-1,statin ( open ),C0360714
-1,standard therapy,C2936643
-1,st change > nmbr mm,C0036056;C0053917;C0392747;C0443172;C1334884;C1705241;C3272372;C4319952;C4330985;C4554674
-1,st - segment depression > nmbr . nmbr mv on admission  %,C0053917;C0520887;C1334884;C1454484;C1705503;C4281602
-1,st ( arc definite only ),C0036056;C0205171;C0439544;C1704787;C1720467;C3272372
-1,spironolactone ( n = nmbr ),C0037982;C0053917;C1334884
-1,smoking status at screening  n ( % ),C0037369;C0220908;C0220909;C0421330;C0453996;C1519386;C1698960;C1710031;C1710032;C1710477;C1881674;C2348164
-1,smoking habit  n ( % ),C4505437
-1,small - artery occlusion ( lacune ),C0001168;C0011382;C0028778;C0226001;C0241970;C0264995;C0441597;C0700321;C1110554;C1947917
-1,small - artery occlusion,C0001168;C0011382;C0028778;C0226001;C0264995;C0441597;C0700321;C1110554;C1947917
-1,single - vessel disease  n ( % ),C0037179;C0042373;C0087136;C0205171
-1,simvastatin monotherapy ( n = nmbr  nmbr * ),C0053917;C0074554;C1334884
-1,short - acting anticholinergics,C0079613;C0242896;C1282927;C1704930;C1806781;C1869853;C2350002;C3537307;C3540711;C3890007;C4048375
-1,sfnmbr - pcs,C1864389;C1882368
-1,sfc nmbr / nmbr | ig bid n = nmbr,C0021027;C0053917;C0305052;C0360506;C1334884;C4521536
-1,sf - nmbrvnmbr domain scores  mean [sd],C0037712;C1880389;C1883221;C3541951
-1,sf - nmbr score,C0037712;C0053917;C0449820;C1334884;C4050231
-1,sf - nmbr physical component summaryjj,C0031809;C0037712;C0053917;C0205485;C0449432;C1334884;C1509143;C1705248
-1,sf - nmbr ( health transition score ),C0037712;C0053917;C0376627;C0449820;C1334884;C4050231
-1,sex : male ( n = nmbr ),C0053917;C0086582;C1334884
-1,sex ( interaction : p = nmbr . nmbr ),C0009253;C0036864;C0053917;C0079399;C0804628;C1314687;C1334884;C1522384;C1704675
-1,sex  n ( % ) male,C0086582
-1,sex  male / female  %,C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
-1,severity of copd  ( gold nmbr )  %,C0018026;C0024117;C0053917;C0439793;C0522510;C1304897;C1334884;C1412502;C3714496
-1,serum pnmbrnp ( ^g / liter ),C0229671;C0439267;C0475211;C1546774;C1550100
-1,serum haemoglobin anmbrc concentration ( % )  mean ( sd ),C0019029;C0019046;C0229671;C0444504;C0683149;C1314664;C1318517;C1546774;C1550100;C2347634;C2348143;C2699239
-1,serum albumin  g nmbr nmbr,C0036773;C0053917;C0439267;C0728877;C1334884
-1,serum albumin  g / dl,C0036773;C0439267;C0728877
-1,seropositive ( rf + ve and / or acpa + ve ) subgroup,C0035448;C0042469;C0201660;C0521143;C0748398;C1547111;C3714652;C4321495
-1,selexipag ( n = nmbr ),C0053917;C1334884;C2000145
-1,selexipag,C2000145
-1,selected medications — no . ( % ),C0013227;C0802604;C1707391;C2598133;C4284232
-1,selected baseline medications,C0013227;C0168634;C0802604;C1442488;C1707391;C2598133;C4284232
-1,seizure types reported during baseline  n ( % ) a,C0036572;C0332307;C1959629;C4553401
-1,secukinumab,C3179547
-1,secondary ( change in total updrs score from baseline to final visit in phase nmbr ),C0027627;C0175668;C0205436;C0392747;C0439175;C0439810;C0443172;C1705241;C3639721;C4319952
-1,screening bmi ( kg / mnmbr ),C0022718;C0220908;C0220909;C0439209;C0578022;C1698960;C1710031;C1710032;C1710477;C2348164;C4054209
-1,score distribution : < nmbr,C0053917;C0449820;C0520511;C1334884;C1704711;C4050231
-1,saxagliptin nmbrmg ( n z nmbr ),C0053917;C1334884;C1611934
-1,saxagliptin nmbr . nmbr mg ( n = nmbr  nmbr ),C0024671;C0026410;C0053917;C0439269;C1334884;C1611934;C1960952;C2346927;C4321396;C4521761
-1,salmeterol nmbr gg bid,C0017454;C0018370;C0053917;C0073992;C1334884
-1,salmeterol - fluticasone group,C0441833;C0687744;C0939232;C1257890;C1519504;C1705428;C1705429
-1,safety population  n ( % ),C0032659;C0036043;C1257890;C1705187
-1,sacubitril / valsartan,C4033631
-1,russia / georgia ( n = nmbr ),C0017452;C0017454;C0035970;C0053917;C1334884
-1,rosuvastatin of patients ( rate ),C0030705;C0871208;C0965129;C1521828
-1,rosuvastatin n = nmbr,C0053917;C0965129;C1334884
-1,rosuvastain + fenofibric acid nmbr = nmbr,C0053917;C0060179;C1334884
-1,rosiglitazone,C0289313
-1,role physical,C0031809;C0035820;C0205485;C1509143;C1705810;C3871154
-1,rivastigmine ( n = nmbr ),C0053917;C0649350;C1334884
-1,rivaroxaban nmbr mg,C0024671;C0026410;C0053917;C0439269;C1334884;C1739768;C1960952;C2346927;C4321396;C4521761
-1,rivaroxaban + aspirin,C0004057;C1739768
-1,risk score category ( points ),C0035647;C0449820;C0683312;C3889287;C4050231;C4552904
-1,risk reduction ( %  nmbr % ci ),C0008107;C0053917;C1137094;C1334884;C3259781
-1,risk reduction  %,C1137094
-1,risk factors  %,C0035648;C1553898
-1,rheumatoid factor positive §  n ( % ),C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
-1,rheumatic heart disease,C0035439
-1,rhabdomyolysis  myopathy  or myalgia with ck elevation > nmbrx uln,C0026848;C0035410;C4552660
-1,rf positive — number ( % ),C0035448;C0201660;C0748398;C1547111;C3812269
-1,rf positive  n ( % ),C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
-1,rf positive  %,C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
-1,rf and acpa negativenmbr,C0035448;C0201660;C0748398;C1547111
-1,retinopathy — %,C0035309;C1962966
-1,rerandomization to placebo ( n = nmbr ) f,C0016327;C0032042;C0053917;C1334884;C1696465;C1706408
-1,reported hypertension *,C0020538;C0684224;C0700287;C1963138;C4319718
-1,renin - angiotensin inhibitors,C0003018;C2917241;C3653375;C4521302
-1,relative risk reduction ( nmbr % cl ),C0053917;C0080103;C0205345;C0242492;C0301630;C0392756;C0596019;C1137094;C1293152;C1334884;C1547039;C4551656
-1,relative decrease > nmbr %,C0053917;C0080103;C0205345;C0392756;C0547047;C1334884;C1547039
-1,region of enrollment  no . ( % ),C0017446;C0205147;C1516879;C1696073;C3888021
-1,region of enrollment  n ( % ) +,C0017446;C0205147;C1516879;C1696073;C3888021
-1,recurrent ischemia - urgent revascularization,C0022116;C0439609;C0581603;C1455761;C2945760;C3272275;C4321499
-1,recent cardioversion ( within nmbr days before randomization ) —,C0013778;C0053917;C0332185;C0439228;C1334884
-1,receiving insulin therapy,C0021641;C0039798;C0087111;C1363945;C1514756;C1533581;C1579433;C3714501
-1,rec . ischemia requiring revasc,C0022116;C0378365;C1424025;C2606415;C4321499
-1,rec . ischemia leading to hasp,C0022116;C1424025;C2606415;C4321499
-1,rec . ischemia due worsening angina,C0002965;C0022116;C0678226;C1424025;C2606415;C3146286;C4321499
-1,ratio of women to men — %,C0043210;C0456603;C1547037
-1,ratio fp / sal : sal ( nmbr % ci ),C0008107;C0016704;C0036140;C0037494;C0053917;C0206136;C0456603;C1334884;C1419068;C1419906;C1547037;C3259781;C3541238;C3541412
-1,rasagiline  nmbr mg / day,C0053917;C0439422;C0525678;C1334884
-1,ranolazine ( n = nmbr  nmbr ),C0053917;C0073633;C1334884
-1,ranolazine  n = inmbrinmbr,C0073633
-1,randomized to receive beta carotene,C0034656;C3815594
-1,randomized to aspirin use,C0004057;C0034656;C0042153;C0457083;C1947944;C3815594
-1,randomized,C0034656;C3815594
-1,randomization to placebo or telmisartan,C0032042;C0034656;C1696465;C1706408
-1,randomization to arterial sheath insertion,C0003842;C0021107;C0034656;C0221464;C0227952;C0441587;C1512796;C1883719
-1,randomization groups nmbr and nmbr,C0034656
-1,randomization - to -,C0034656
-1,randomisation visit ( baseline ),C0034656;C0168634;C0545082;C1442488;C1512346;C2826704
-1,radius fracture,C0034628
-1,race or ethnic group ( % ),C0034510;C1706779;C3853635
-1,race or ethnic group,C0034510;C1706779;C3853635
-1,race and ss at baseline,C0034510;C1706779;C3853635
-1,race / ethnicity  %,C0015031;C0034510;C0243103;C1706779;C3853635
-1,race - non - white ( n = nmbr  nmbr ),C0034510;C1706779;C3853635
-1,race  white  n ( % ),C0034510;C1706779;C3853635
-1,qualifying nstemi  n ( % ),C1514624;C3537184;C4255010
-1,py = nmbr . nmbr ),C0030428;C0053917;C1334884;C3538810
-1,pulse rate ( bpm ),C0232117
-1,pulmonary rales  n ( % ),C0034642
-1,pulmonary rales,C0034642
-1,pulmonary function tests  % of predicted,C0024119;C0681842;C1882327;C2598152
-1,pulmonary embolism ± deep vein thrombosis,C0034065;C0149871;C0226514;C0852030
-1,pulmonary embolism,C0034065
-1,pulmonary disease,C0024115
-1,puerperium,C0034042;C0086839;C1879329
-1,ptca or pci,C2936173
-1,psychosocial risk factors,C0033963;C0035647;C0035648;C0542298;C1458132;C1553898;C4552904
-1,psoriatic arthritis pain],C0003872;C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4317006;C4553004;C4554132
-1,psoriasis duration  yrs *,C0033860;C0449238;C2926735
-1,psoriasis duration  mean ± sd  years,C0033860;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
-1,psoriasis covering > nmbr % bsa  n ( % ) §,C0033860;C0053917;C0180153;C0439844;C1334884
-1,psoriasis body surface area > nmbr %,C0005902;C0033860;C0053917;C1334884
-1,proportion of predicted normal fevnmbr value   §,C0086715;C0681842;C1709707;C1882327
-1,profound thrombocytopenia ( < nmbrxnmbr / l ),C0040034;C0392386;C0439808
-1,proctosigmoiditis,C0033252
-1,procedures for index event,C0025664;C0184661;C0441471;C0600653;C0918012;C1552854;C1637833;C2700391;C2986546;C3538935;C4019010
-1,procedure,C0184661;C2700391;C3274430;C3539779
-1,proactive intervention ( n = nmbra ),C0184661;C0886296;C1273869
-1,prior use of biologics  n ( % ),C0005515;C0005522;C0332152;C1524063;C2826257;C4553887
-1,prior use of biologic agents,C0005515;C0332152;C1524063;C2826257
-1,prior therapy with tnf antagonist  n ( % ),C0231491;C0279936;C0332152;C1448177;C1514463;C2826257
-1,prior stroke or transient ischemic attack,C0038454;C0332152;C2826257;C4554100
-1,prior percutaneous coronary intervention  n ( % ),C0332152;C1532338;C2826257
-1,prior ml ( before index acs ),C0332152;C0439526;C0600653;C0742343;C0918012;C1552854;C1637833;C1705224;C2826257;C2986546;C3887665;C4318612
-1,prior medications,C0013227;C0332152;C0802604;C2598133;C2826257;C4284232
-1,prior lipid - modifying therapy,C0023779;C0392747;C1514463
-1,prior diabetes,C0011847;C0011849;C0332152;C2826257
-1,prior cv event at randomization !,C0034656;C0332152;C0441471;C2826257;C3538987;C4019010;C4048877;C4318503
-1,prior corticosteroid failure only,C0001617;C0205171;C0231174;C0332152;C0680095;C1720467;C2826257;C3536709
-1,prior coronary artery bypass graft surgery,C0010055;C0332152;C2826257
-1,prior congestive heart failure,C0018802;C0332152;C2826257
-1,prior cerebrovascular disease,C0007820;C0332152;C2826257
-1,prior carotid intervention,C0184661;C0332152;C0741968;C0886296;C1273869;C2826257
-1,prior cardiac surgery  n ( % ),C0018787;C0018821;C0332152;C0455610;C0524727;C1522601;C2826257
-1,prior antihypertensive medication  n ( % ),C0003364;C0332152;C2826257
-1,primary renal endpoint or death,C0022646;C2986535
-1,primary prevention subgroup,C0033144;C1079230;C1515021
-1,primary ep ( cvd / mi / ri ),C0007222;C0035487;C0205225;C0439612;C0439631;C1826843;C1880476;C3810814;C4321526
-1,primary + gusto severe bleeding,C0019080;C0205082;C0205225;C0439612;C0439631;C4050465;C4050466
-1,previous vascular disease,C0042373;C0205156;C1552607
-1,previous treatment with tnf antagonist — no . ( % ) §,C0039798;C0087111;C0205156;C0231491;C1448177;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
-1,previous transient ischaemic attack / ischaemic stroke previous warfarin use,C0007787;C0038454;C0042153;C0043031;C0205156;C0457083;C0917805;C1552607;C1947944;C4554100
-1,previous stroke ortransient ischaemic attack ( % ),C0038454;C0205156;C0745413;C1552607;C4554100
-1,previous percutaneous coronary intervention,C0205156;C1532338;C1552607
-1,previous oral glucose - lowering agents  % of patients,C0205156;C0441994;C0600419;C1552607;C1955477;C2003888
-1,previous myocardial infarction — no . ( % ),C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
-1,previous myocardial infarction ( % ),C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
-1,previous medications  n ( % ),C0013227;C0205156;C0802604;C1552607;C2598133;C4284232
-1,previous major bleeding,C0019080;C0205082;C0205156;C0205164;C1552607;C4318856;C4521762
-1,previous hypertension,C0020538;C0205156;C1552607;C1963138
-1,previous hf hospitalization  n ( % ),C0018488;C0019993;C0205156;C1313497;C1538440;C1552607;C3273279
-1,previous dmards use  n ( % ),C0205156;C0242708;C1552607
-1,previous disease :,C0012634;C0205156;C1552607
-1,previous deep - vein thrombosis or pulmonary embolism,C0149871;C0205156;C1552607
-1,previous copd treatment  n ( % ) *,C0024117;C0039798;C0087111;C0205156;C1412502;C1522326;C1533734;C1552607;C1705169;C3538994;C3714496;C3887704
-1,previous cardiovascular disease !,C0007222;C0205156;C1552607
-1,previous antiarrhythmic treatment — no . ( % ),C0003195;C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3537142;C3538994;C3887704
-1,preoperative heart rate ( beats per minute ),C0018810;C0445204
-1,preoperative blood pressure ( mm hg ) patients fulfilling eligibility criteria,C0005823;C0030705;C0439475;C0445204;C1271104;C1272641
-1,predominant type of heparin,C0019134;C0332307;C0770546;C1542147;C1547052
-1,pre - randomization pci,C0034656;C0332152;C0740175;C2257086;C3669034;C4049621
-1,pre - bronchodilator fevnmbr / fvc ratio *,C0456603;C1547037;C2599602;C3714541
-1,prasugrel,C1620287
-1,potassium - sparing at last follow - up,C0032821;C0202194;C0304475;C0589120;C0597277;C1522577;C1704685;C3274571;C3714637
-1,potassium - sparing at enrollment,C0032821;C0202194;C0304475;C0597277;C1516879;C1696073;C3714637;C3888021
-1,potassium,C0032821;C0202194;C0304475;C0597277;C3714637
-1,postoperative glucocorticoid use,C0017710;C0032790;C0042153;C0457083;C1947944
-1,postmenopausal hormone use,C0019932;C0042153;C0232970;C0457083;C1947944;C4521914
-1,postmenopausal  current hormone,C0019932;C0232970;C0521116;C1705970;C4521914
-1,postbronchodilator lung function at screening,C0035245;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594
-1,post - bronchodilator fvc ( l ) a,C2599594;C3714541
-1,post - bronchodilator fevnmbr  reversibility percentage of baseline value,C0168634;C0439165;C0449261;C1442488;C1522609;C1549488;C1561533;C2599594
-1,pooled simvastatin factorial studies,C0074554;C1709595;C2349200;C2826344;C4522255
-1,pooled empagliflozin ( n = nmbr ),C0053917;C1334884;C1709595;C2349200;C3490348;C4522255
-1,planned thienopyridine at baseline,C0168634;C1120149;C1301732;C1442488
-1,placebo secukinumab pooled,C0032042;C1696465;C1706408;C3179547
-1,placebo secukinumab nmbr mg,C0024671;C0026410;C0032042;C0053917;C0439269;C1334884;C1696465;C1706408;C1960952;C2346927;C3179547;C4321396;C4521761
-1,placebo plus aspirin,C0004057;C0032042;C0332287;C1696465;C1706408
-1,placebo no . of events / total no . ( % ),C0032042;C1696465;C1706408
-1,placebo no . / total ( % ),C0032042;C1696465;C1706408
-1,placebo mean ( n ),C0032042;C0444504;C1696465;C1706408;C2347634;C2348143
-1,placebo ls means ( n ),C0023668;C0032042;C1696465;C1704970;C1706408
-1,placebo every nmbr weeks ( n = nmbr ),C0032042;C1696465;C1706408
-1,placebo estimated mean,C0032042;C1696465;C1706408
-1,placebo + mtx,C0025677;C0032042;C1417487;C1696465;C1706408
-1,placebo ( dm - vs . dm + ),C0011816;C0032042;C1696465;C1706408;C3250443
-1,placebo  n ( rate ),C0032042;C0871208;C1521828;C1696465;C1706408
-1,pioglitazone pts / n ( % ),C0071097;C1419129;C2698747
-1,pioglitazone events / n ( % ),C0071097;C0441471;C3541888
-1,physician ' s judgment that vka,C0022423;C0031831;C0804815
-1,physician ' s global assessment of dis -,C0451119;C1444662;C1970187;C4050369
-1,physical function ( nmbr - nmbr  short form - nmbr subscale ),C0031843;C0053917;C0348078;C0376315;C0516981;C0542341;C0597240;C0700205;C0700329;C1282927;C1334884;C1522492;C1705273;C1806781;C2350002;C4049916;C4255237
-1,physical component,C0031809;C0205485;C0449432;C1509143;C1705248
-1,phosphorus  mmol nmbr nmbr,C0031705;C0053917;C0080014;C0439190;C1334884;C3714498
-1,phospholipid omega - nmbr levels : < nmbr % ( n = nmbr ),C0031676;C0053917;C0202177;C0441889;C1334884;C1719844
-1,philippines,C0031529
-1,phenytoin,C0031507;C0202454
-1,persistent anemia bsl hb < nmbrg i - nmbr  yr nmbr < nmbrg i nmbr,C0019046;C0021966;C0053917;C0221138;C0439234;C0741008;C1334884;C1549954
-1,permanently stopped study drug because of adverse events,C0041755;C0557651;C1272691;C2603343
-1,periprocedural medications — no . / total no . ( % ),C0013227;C0802604;C2598133;C4284232
-1,periprocedural medications — no . / total no .,C0013227;C0802604;C2598133;C4284232
-1,peripheral - artery disease ( % ),C1704436;C4025272
-1,peri - op amiodarone : no ( n = nmbr ),C0002598;C0347985
-1,percutaneous coronary intervention or coronary artery bypass graft surgery  n ( % ),C1532338
-1,percutaneous coronary intervention,C1532338
-1,pef  post - bronchodilator  % predicted normal,C0030771;C1518922;C1542834
-1,peak procedural act — sec,C0025664;C0184661;C0444505;C2700391;C3274430;C3538935;C3539779
-1,peak creatine kinase - mb  u / l,C0010290;C0439339;C0444505;C0523584
-1,pav  mean ( nmbr % ci ),C0008107;C0053917;C0058890;C0444504;C1334884;C2347634;C2348143;C3259781
-1,patients without ra  as  or psa ( n = nmbr  nmbr ),C0030705;C3538806;C4048756
-1,patients with previous loss of response to and intolerance of infliximab *,C0030705;C0205156;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692
-1,patients with diabetic nephropathy,C0011881;C0030705;C1442864
-1,patients treated with insulin,C0030705
-1,patients treated for > nmbr weeks ( % ),C0030705
-1,patients receiving corticosteroids at baseline,C0030705
-1,patients not receiving corticosteroids at baseline,C0030705
-1,patient history of disease n ( % ),C0030705;C0683519;C0730226;C0850708;C0944983
-1,patient history of disease,C0030705;C0683519;C0730226;C0850708;C0944983
-1,patent foramen ovale,C0016522;C0344724
-1,partial mayo clinic scored,C0002424;C0442592;C0454788;C0728938;C1077578;C1550516
-1,parenteral anticoagulalion before randomization,C0030547;C0034656;C4522267
-1,parental history of myocardial infarction before nmbr yr of age ( % ),C0030551;C1275835
-1,paracetamol,C0000970
-1,pancreatic cancer,C0235974;C0346647;C2984259
-1,paclitaxel - eluting,C0144576
-1,pacific islander,C0242191
-1,p value ( men versus women ),C0025266;C1709380
-1,p - val . ( nmbr ),C0042285;C0053917;C0369773;C0523975;C1334884;C2603361
-1,oxidative stress,C0242606
-1,other vascular disease — no . ( % ),C0042373
-1,other statin,C0360714
-1,other nsaids,C0003211
-1,other lipid parameters,C0023779;C0449381
-1,other lipid - modifying drug use at study entry  n ( % ),C0013175;C0013227;C0023779;C0042153;C0242510;C0392747;C0457083;C0557651;C0869040;C1254351;C1705654;C1947944;C2603343
-1,other glp - nmbr receptor agonist,C0018301;C0053917;C1334884;C1422069;C1425391;C1539338;C2350813;C4543206
-1,other drugs,C0013227;C3687832
-1,other biologic agent,C0005515
-1,other asian,C0078988
-1,other anticoagulant,C0003280;C0848112;C3536711
-1,other antiarrhythmics^,C0003195
-1,osteoporosis,C0029456;C4554622
-1,orthostatic hypotension,C0020651
-1,oral study drug administered — no . / total no . ( % ),C0013175;C0442027;C4521986
-1,oral contraceptives,C0009905
-1,only peripheral artery disease,C0205171;C1704436;C1720467;C4025272
-1,one - third radius,C0034627;C0205437;C0205447;C1306504
-1,odds ratio versus placebo ( nmbr % ci ),C0028873
-1,odds ratio adj ( nmbr % cl ),C0001552;C0028873;C0053917;C0596019;C1334884;C2826286
-1,odds ratio,C0028873
-1,obesity ( body mass index > nmbr kg / mnmbr ),C0005893;C0022718;C0028754;C0053917;C0439209;C0578022;C1305855;C1334884;C1963185;C4054209
-1,obesity  % *,C0028754;C1963185
-1,oad plus insulin,C0021641;C1533581;C1579433;C3714501
-1,number of vessels disease,C0042373;C0237753;C0449788
-1,number of treated vessels ( per patient ),C0005847;C0237753;C0449788;C1522326
-1,number of stents implanted,C0038257;C0237753;C0449788
-1,number of stent = nmbr,C0038257;C0053917;C0237753;C0449788;C1334884
-1,number of previous anti - tnf treatments for psoriatic arthritis,C0087111;C0205156;C0237753;C0449788;C1448177;C1552607
-1,number of events / patients,C0030705;C0441471;C2360800;C3541888;C4330837
-1,number of concomitant aeds  n ( % ),C0180309;C0237753;C0449788;C0521115
-1,number of antidiabetes drugs at screening  n ( % ),C0013227;C0237753;C0449788;C3687832
-1,number of ( % ) females,C0086287;C0237753;C0449788
-1,nt - probnp pg / mla ( iqr ),C0030827;C0072225;C0599973;C0669479;C0754710;C1266240
-1,nsaid use — no . / total no . ( % ),C0003211;C3536840
-1,notable abnormalities,C0000768;C0000769;C4288581
-1,normoalbuminuria at baseline ( nmbr % of patients treated ),C0030705;C0053917;C0168634;C1334884;C1442488
-1,normal troponin,C0041199;C0205307;C0231683;C0439166;C2347086;C4553972
-1,normal fasting glucose level ( n = nmbr ),C0015663;C0053917;C0202045;C0205307;C0231683;C0439166;C0522082;C1334884;C2347086;C4553972
-1,normal / mild ckd,C0205307;C0231683;C0439166;C1561643;C2347086;C2945599;C4553972
-1,nonaspirin antiplatelet agent,C0085826;C0722138
-1,non – small - cell lung cancer,C0007131;C2984258;C3539721
-1,non - sulfonylurea secretagogues,C0038766;C1518422;C3536898;C4704833
-1,non - smoker ( n = nmbr  nmbr ),C0053917;C0337672;C0425293;C1334884;C4554605
-1,non - fatal myocardial infarction,C0027051;C0428953;C1302234;C1518422;C1705232;C2926063;C3810814;C4552959
-1,no statin vs statin alone vs any statin plus other llt,C0360714
-1,no prior hf hospitalization ( n = nmbr  nmbr ),C0018488;C0019993;C0053917;C0332152;C1313497;C1334884;C1538440;C2826257;C3273279
-1,no pah therapy,C0030123;C0039798;C0087111;C1363945;C3203102;C4284467
-1,no corticosteroid + no imm  n,C0001617;C3536709
-1,no concomitant cortcosteroid use,C0042153;C0457083;C0521115;C1947944
-1,no antidiabetic drug,C0935929
-1,no . of risk factors ( % ) | |,C0035648;C1553898
-1,no . of previous anti - tnf drugs — no . ( % ),C0013227;C0205156;C1448177;C1552607;C3687832
-1,no . of predictors of cardiovascular risk,C0007226;C0035647;C2698872;C3887460;C4552904
-1,no . of patients / total no . ( % ),C0030705
-1,nmbr mg cohort,C0009247;C0024671;C0026410;C0053917;C0439269;C0599755;C1334884;C1960952;C2346927;C4321396;C4521761
-1,nmbr = minor symptoms  no limitations,C0026193;C0053917;C0205165;C0683368;C1334884;C1457887
-1,nmbr - nmbr with cv disease ( n = nmbr ),C0007222;C0053917;C1334884
-1,nmbr - h plasma glucose during ogtt ( mmol / l ),C0029161;C0053917;C0202042;C0455280;C1334884;C2827804
-1,nitrates ( oral or topical ),C0028125;C0699857;C3848573
-1,nitrate — no . ( % ),C0028125;C0699857;C3848573
-1,nicotine pack - years,C0028040;C1277691
-1,never used lev,C0023556;C1273517;C2003901
-1,neuropilin ( ng / ml ),C0287275;C0439275
-1,neoplasia  n ( % ),C0027651;C1882062
-1,neoplasia,C0027651;C1882062
-1,neither pbo + statin eze + statin,C0031962;C0360714
-1,neither glucocorticoids nor immunosuppressive agents,C0017710;C3540777;C3540778
-1,ncep risk category at study entry  n ( % ),C0035647;C1705654;C2983287;C2983669;C4552904
-1,native hawaiian or other pacific islander,C0337920
-1,native hawaiian / other,C0337920
-1,native coronary - artery lesions,C0205042;C0221198;C0302891
-1,nationality,C0027473
-1,nasal polyps,C0027430
-1,nadroparin vs control,C0206232
-1,n ( indacaterol nmbr ug / indacaterol nmbr ug / placebo ),C0032042;C0053917;C0369718;C0441922;C1319635;C1334884;C1696465;C1706408;C1722260
-1,myocardial infarction — no . ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
-1,myocardial infarction within the previous nmbr yr,C0027051;C0053917;C0205156;C0428953;C0439234;C1334884;C1552607;C2926063;C3810814;C4552959
-1,mycophenolate mofetil,C0209368
-1,muscle spasms,C0037763
-1,multivessel intervention  n ( % ),C0184661;C0886296;C1273869
-1,mucolytic agent,C0026698
-1,mtx exposure ( mg / week ),C0024671;C0025677;C0026410;C0274281;C0332157;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
-1,mtx + non - mtx,C0025677;C1417487;C1518422
-1,mri substudy ( n = nmbr ),C0024485;C0053917;C1334884;C1824234;C3890166
-1,montelukast ( n = nmbr ),C0053917;C0298130;C1334884
-1,moderate thrombocytopenia ( < nmbrxnmbr / l ),C0040034;C0205081;C0392386;C1881878;C4049705;C4049706;C4085643;C4321335
-1,moderate risk,C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
-1,moderate ( nmbr risk factor ),C0035648;C0053917;C0205081;C1334884;C1881878;C4049705;C4049706;C4085643;C4321335
-1,mixed chronic bronchitis and emphysema,C0008677;C0205430;C3160715
-1,minimum stent diameter,C0038257;C4054490
-1,mini - mental state examination,C0451306
-1,microvascular eye diseased,C0015392;C0443258;C0700042
-1,microvascular complications  n ( % ) ’,C0009566;C0443258;C1171258
-1,micro - / macro - albuminuria  ckd and / or retinopathy,C0001925;C0085672;C1553035;C1561643;C2984010;C3811161;C4049106
-1,metrex overall modified intention - to - treat population ? :,C0032659;C0087111;C0162425;C0282416;C0392747;C1257890;C1283828;C1292734;C1522326;C1561607;C3889737
-1,methotrexate dose at baseline,C0025677;C0168634;C0178602;C0869039;C1114758;C1442488
-1,metformin dose  mg,C0024671;C0025598;C0026410;C0178602;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
-1,metabolizer phenotype ( % ) §,C0031437;C1285572
-1,metabolic syndrome characteristics  n ( % ),C0524620;C1521970
-1,metabolic syndrome ( > nmbr of nmbr characteristics ),C0053917;C0524620;C1334884;C1521970
-1,mesothelin ( ng / ml ),C0380162;C0439275;C1334533
-1,mepolizumab  nmbr mg ( n = nmbr ),C0024671;C0026410;C0053917;C0439269;C0969324;C1334884;C1960952;C2346927;C4321396;C4521761
-1,men  total ( n 二 nmbr ),C0025266;C0053917;C0439175;C0439810;C1334884
-1,medium - or low - intensity statin,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
-1,medications at randomization,C0013227;C0034656;C0802604;C2598133;C4284232
-1,medication use — no . ( % ),C0013227;C3244316;C4284232
-1,medication use at baseline — no . ( % ),C0168634;C0240320;C1442488
-1,medication taken alone or in combination,C0013227;C3244316;C4284232
-1,medication at enrollment — no . ( % ),C0013227;C1516879;C1696073;C3244316;C3888021;C4284232
-1,medication adherence,C2364172
-1,medical conditions  no . ( % ),C0012634;C0199168;C0205476;C0348080;C1705253;C3864998
-1,median serum periostin  ng / mla,C0017887;C0028074;C0219433;C0229671;C0549183;C0599973;C0876920;C1424662;C1546774;C1550100;C2347635;C2348144;C2939193;C3812270
-1,median fasting insulin ( iqr ) — pu per milliliter,C0015663;C0018387;C0021641;C0439242;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501
-1,median duration of study - drug administration,C0013175;C0549183;C0876920;C2347635;C2348144;C2348354;C2939193
-1,median ( qnmbr : qnmbr ) total daily insulin dosenmbr,C0021641;C0332173;C0439175;C0439810;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501
-1,median ( qnmbr : qnmbr ) tg - rich lipoprotein cholesterol,C0065055;C0337445;C0549183;C0699759;C0876920;C2347635;C2348144;C2939193
-1,median ( qnmbr : qnmbr ) duration of insulin use  years,C0021641;C0439234;C0549183;C0876920;C1533581;C1579433;C1881378;C2347635;C2348144;C2826775;C2939193;C3714501
-1,mean ± sd waist circumference  cm,C0444504;C0455829;C2347634;C2348143;C2699239
-1,mean ± sd triglycerides  mg / dl,C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
-1,mean ± sd bmi  kg / mnmbr,C0022718;C0439209;C0444504;C0578022;C2347634;C2348143;C2699239;C4054209
-1,mean ± s . d . duration of diabetes  years,C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2926735
-1,mean pulse pressure  mmhg ( s . d . ) “,C0232117;C0391850;C0444504;C0445074;C0949236;C1947910;C2347155;C2347634;C2348143
-1,mean platelet volume  fl,C0200665;C0344388;C1300812;C1708024
-1,mean lipid values  mg / dl,C0023779;C0042295;C0439269;C0444504;C2347634;C2348143
-1,mean blood pressure  mmhg ( s . d . j,C0428886;C0488053;C2347155
-1,mean baseline ibdq score ( sd ) § crp concentration  mg / l,C0086045;C0168634;C0439268;C1442488;C1446561;C2699239;C3533236;C3827302;C3890735;C4048285
-1,mean ( sd ) number of albuterol per day  puff,C0001927;C0237753;C0444504;C0449788;C2347634;C2348143;C2699239
-1,mdi / hfa  n,C0015458;C0993596;C1839839;C4049613
-1,management of event — no . ( % ),C0001554;C0376636;C0441471;C1273870;C3273539;C4019010
-1,male sex — no . ( % ) race — no . ( % ) ) :,C0086582
-1,major cvd /,C0007222;C0205082;C0205164;C4318856;C4521762
-1,major bleeding ( statin use vs non - use ),C0019080;C0042153;C0205082;C0205164;C0360714;C0457083;C1947944;C4318856;C4521762
-1,lv mass index ( g / mnmbr - nmbr ),C0053917;C0439267;C0455825;C0600653;C0918012;C1334884;C1552854;C1637833;C2986546
-1,lv hypertrophy  n ( % ),C0149721
-1,lumbar spine,C0024091;C3887615
-1,ls mean difference ± seb,C0023668;C0059386;C0444504;C1309881;C1423585;C1705241;C1705242;C2347634;C2348143;C3815268
-1,ls mean ( s . e . ) primary endpoint : % change from baseline to week nmbr,C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C2986535;C4319952
-1,ls mean % change from baseline _ se,C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
-1,lp ( a )  mean ( sd ),C0065058;C0444504;C1439335;C2347634;C2348143;C2699239;C4553379
-1,lower - limb arterial — no . ( % ),C0023216
-1,low molecular weight ( lmw ) heparin before randomisation,C0019139;C0034656;C3536766
-1,low density lipoprotein cholesterol  mg / dl * *,C0023824;C0439269
-1,low - molecular - weight,C0026385;C0041667;C0205251;C1521991;C1550472;C3890211;C4048187;C4321351;C4522223
-1,low - dose rivaroxaban plus aspirin ( n = nmbr ),C0053917;C0332287;C1334884;C1739768;C2608320
-1,low - dose rivaroxaban + aspirin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1739768;C2608320
-1,low - dose rivaroxaban + aspirin ( n / n ),C1739768;C2608320
-1,low - dose corticosteroid user,C0001617;C0445550;C1548600;C1706077;C1708745;C3536709
-1,low - dose aspirin use at baseline yes,C0042153;C0168634;C0457083;C1442488;C1549445;C1705108;C1710701;C1947944;C2608320
-1,low - density lipoprotein cholesterol  mg / dl,C0023824;C0439269
-1,low - density lipoprotein cholesterol  %,C0023824
-1,losmapimod,C3272847
-1,losartan n = nmbr,C0053917;C0126174;C1334884
-1,losartan + placebo,C0032042;C0126174;C1696465;C1706408
-1,long - acting or short - acting nitrates,C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
-1,location of crohn ' s disease  %,C0010346;C0450429;C1515974;C4284930;C4284931
-1,llv wlalil nmbr statin,C0053917;C0360714;C1334884
-1,liraglutide nmbr . nmbr mg ls means ( n ),C0023668;C0024671;C0026410;C0053917;C0439269;C1334884;C1456408;C1704970;C1960952;C2346927;C4321396;C4521761
-1,lipoprotein ( a ) tx difference vs pbo  ls mean % change from baseline ( se ),C0041403;C0065058;C0125953;C1096202;C1439335;C1705241;C1705242
-1,lipid profile,C0023779;C1979963;C2003903
-1,lipid lowering medication use,C0023779;C0240320;C0441994;C2003888
-1,lipid - lowering medication ( % ),C0013227;C0023779;C0441994;C2003888;C3244316;C4284232
-1,lipid - lowering agents ( % ),C0086440
-1,limb ( sd ),C0015385;C2699239
-1,level of renal impairment,C0441889;C0456079;C1547707;C1565489;C2946261
-1,lev status  n ( % ),C0023556;C0449438
-1,leukocytes  nmbr / nl,C0023516;C0027778;C0053917;C0560008;C1334884;C3892223
-1,length of stay ( randomization to discharge  h ),C0023303;C0034656
-1,leisure,C0086542
-1,left ventricular hypertrophy — no . ( % ),C0149721;C3484363
-1,left ventricular hypertrophy ( % ),C0149721;C3484363
-1,left ventricular ejection fraction within previous nmbr mo |,C0026544;C0053917;C0205156;C0332177;C0428772;C0488728;C1334884;C1552607
-1,left ventricular ef  mean ( sd )  %,C0225897;C0444504;C2347634;C2348143;C2699239
-1,left main artery,C0003842;C0205091;C0205225;C0226004;C0443246;C1542147;C1552822
-1,left bundle - branch block,C0023211;C0344420;C2828132
-1,left atrial diameter  mm ( sd ),C0225860;C0225861;C1301886;C2699239;C4330985;C4554674
-1,left atrial diameter,C0225860;C0225861;C1301886
-1,left - sided disease only,C0012634;C3842976
-1,leflunomide ( mean dose : nmbr . nmbr mg / day ),C0053917;C0063041;C0178602;C0439422;C0444504;C0869039;C1114758;C1334884;C2347634;C2348143
-1,lebrikizumab ( n = nmbr ),C0053917;C1334884;C2981360
-1,least square mean ( se ),C0023189;C0036919;C0444504;C2347634;C2348143
-1,ldl cholesterol — mg / dl | |,C0023824;C0202117;C0439269
-1,ldl cholesterol mean ( mg / dl ± sd ),C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239
-1,latin america hr ( nmbr % cl ),C0023122;C0053917;C0596019;C1334884
-1,laboratory values at randomization ( median and iqr ),C0022877;C0034656;C0042295;C0549183;C0876920;C2347635;C2348144;C2939193;C3244292;C4283904
-1,laboratory values,C0022877;C0042295;C3244292;C4283904
-1,laboratory data  mean ( sd ),C0022877;C0444504;C1511726;C2347634;C2348143;C2699239;C3244292;C3245479;C3714741;C4283904
-1,laboratory data,C0022877;C1511726;C3244292;C3245479;C3714741;C4283904
-1,laba / ics use at screening  n ( % ),C0815320;C4551720
-1,laba + ics ( free or fixed - dose combination ),C0815320;C4551720
-1,laba + ics,C0815320;C4551720
-1,known duration of diabetes  yr,C0011847;C0011849;C0205309;C0439234;C0449238;C2926735
-1,key secondary end point : st,C0036056;C3272372;C4528314
-1,joint damage outcomes ( mitt population ),C0010957;C0022417;C0032659;C0392905;C1257890;C1274040;C1706309;C1883709
-1,ivabradine group,C0257190;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
-1,ivabradine ( n = nmbr ),C0053917;C0257190;C1334884
-1,isolated pulmonary embolism,C0034065;C0205409;C1548221
-1,ischemic cerebrovascular disease  n ( % ),C0007820;C0475224
-1,ischemic aetiology  n ( % ),C0015127;C0475224;C1314792;C1524003
-1,ipf - related,C0034069;C1800706
-1,involved intestinal area  n ( % ),C0021853;C1879646
-1,investigator - reported hypoglycaemia *,C0035173
-1,intravenous dobutamine,C0012963;C0348016
-1,intravenous anticoagulant during hospitalization,C0003280;C0019993;C0348016;C0848112;C3536711
-1,intestinal area involved  n ( % ) $,C0017446;C0021853;C0205146
-1,intervention group ( n = nmbr ),C0053917;C0184661;C0441848;C0886296;C1273869;C1334884
-1,interval study drug to pci,C0013175;C1272706;C1552654;C1552713;C4049621
-1,interval clopidogrel to pci,C0070166;C1272706;C1552654;C1552713;C4049621
-1,intermittent claudication,C0021775
-1,interleukin - nmbr ( ng / l ),C0021764;C0053917;C0439297;C1334884;C1527200
-1,intent of early invasive strategy  %,C0162425;C0205281;C0679199;C1279919;C1283828;C1334278;C1550453
-1,intensive control,C0162425;C0243148;C0522510;C1283828;C1550141;C1550453;C1882979;C2587213;C3274648;C4553389
-1,intense physical activity,C0015259;C0026606;C0522510
-1,insulin and oral hypoglycemic drugs,C0021641;C1533581;C1579433;C3714501
-1,insulin : glucose ratio,C0017725;C0021641;C0456603;C1533581;C1547037;C1579433;C3714501
-1,insulin - na ' ive,C0021641;C0597484;C1272460;C1533581;C1546968;C1579433;C1879645;C3435805;C3714501;C4049872;C4552882;C4554334
-1,insulin + oad,C0021641;C1533581;C1579433;C3714501
-1,insulin ( pmol / l ) t vital signs,C0021641;C0150404;C0439284;C0518766;C1533581;C1579433;C3714501
-1,initiation of insulin,C0021641;C0589507;C1158830;C1533581;C1579433;C1704686;C3714501
-1,initiation of dialysis  renal transplantation  or creatinine . nmbr . nmbr mg / dl ( nmbr mmol / l ),C0011945;C0011946;C0019004;C0022671;C0040732;C0040733;C0589507;C1059964;C1158830;C1704686;C4551529
-1,initial aspirin — no . ( % ),C0004057;C0205265;C1279901;C1555582;C1705685
-1,inhaled anticholinergic §,C0004048;C0242896;C3537004
-1,infarct characteristics,C0021308;C1521970
-1,individuals with diabetes  n = nmbr,C0011847;C0011849;C0027361;C0053917;C0237401;C1334884
-1,indication for stent,C0038257;C0392360;C3146298
-1,indacaterol nmbr mg[n z nmbr],C0024671;C0026410;C0053917;C0439269;C1334884;C1722260;C1960952;C2346927;C4321396;C4521761
-1,indacaterol nmbr gg qd,C0017454;C0018370;C0053917;C0332173;C1334884;C1722260
-1,increased waist circumference,C0205217;C0442805;C0455829
-1,in ibdq total score at week nmbr  mean [se],C0036919;C0053917;C0332174;C0439175;C0439230;C0439810;C0444504;C1334884;C2347634;C2348143;C2964552;C3533236
-1,implantable cardioverter - defibrillator,C0162589;C2825184
-1,impaired glucose tolerance or impaired fasting glucose — no . ( % ),C0271650
-1,immunomodulatory agents,C0005525
-1,ii - iv ( % ),C0022326;C1710602;C4082587;C4265176
-1,iglar dose at randomization ( u / day ),C0034656;C0178602;C0456683;C0869039;C1114758
-1,iglar ( insulin glargine lnmbr u ),C0439148;C0907402
-1,ics use at screening  n ( % ),C0815320;C4551720
-1,ics  mg / day,C0439422;C0815320;C4551720
-1,icd therapy vs . placebo no . hazard ratio ( nmbr . nmbr % cl ),C0021122;C0039798;C0087111;C1363945
-1,hypoglycaemic agents,C0020616
-1,hypertension — no . ( % ) hypercholesterolemia — no . ( % ),C0020538;C1963138
-1,hypertension and left ventricular hypertrophy,C0020538;C1963138
-1,hypertension : no ( n = nmbr ),C0020538;C1963138
-1,hypertension ( n 二 nmbr ),C0020538;C0053917;C1334884;C1963138
-1,hyperkalemia ( > nmbr . nmbr meq / l ),C0020461;C0053917;C0439375;C1334884;C4552983
-1,hydralazine,C0020223
-1,hscrp < nmbr . nmbr mga . nmbr ( nmbr . nmbrxnmbr ( nmbr . nmbr ),C0053917;C0065879;C1334884
-1,hospitalized for asthma  n ( % ) *,C0004096;C0701159;C2984299
-1,hospital factor # nmbr,C0019994;C0053917;C1334884;C1510665;C1521761;C2827422
-1,hosp . for hf,C0018488;C1313497;C1538440;C3273279
-1,homajr tx difference vs pbo  median change from baseline ( se ) nmbr lipid parameters,C0041403;C1705241;C1705242
-1,homa_ % b tx difference vs pbo  median change from baseline ( se ) nmbr,C0041403;C1705241;C1705242
-1,history of peripheral arterial disease ( % ),C0003842;C0205100;C0221464;C0683519;C0730226;C0850708;C0944983
-1,history of microvascular eye disease 本  n ( % ),C0015392;C0015397;C0019664;C0019665;C0262512;C0262926;C0443258;C0683519;C0700042;C0730226;C0850708;C0944983;C1705255;C2004062
-1,history of major bleeding,C0019080;C0019664;C0019665;C0205082;C0205164;C0262512;C0262926;C1705255;C2004062;C4318856;C4521762
-1,history of dyspepsia,C0013395;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4552968
-1,history of chronic hf,C0018488;C0019664;C0019665;C0205191;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279
-1,history of cabg surgery  n ( % ),C0010055;C0455610
-1,history of cabg surgery,C0010055;C0455610
-1,history of bone disease ( predefined )  n ( % ),C0005940;C0019664;C0019665;C0262512;C0262926;C0262950;C0683519;C0730226;C0850708;C0944983;C1705255;C2004062
-1,hispanic ethnic group — no . ( % ) f,C0015031;C0086409;C1879937
-1,hispanic / latin american,C0019576
-1,hispanic ( n = nmbr ),C0053917;C0086409;C1334884
-1,hispanic,C0086409
-1,high risk with atherosclerotic vascular disease *,C0004153;C0332167;C3272283;C4050568;C4319571
-1,high density lipoprotein cholesterol  mg / dl^,C0023822;C0439269
-1,high - intensity statin vs medium - or low - intensity statin at randomization,C0360714;C4081854
-1,high - density lipoprotein cholesterol mean ( mg / dl ± sd ),C0023822;C0439269;C0444504;C2347634;C2348143;C2699239
-1,high - density lipoprotein cholesterol  mg / l,C0023822;C0439268
-1,heterogeneity / trend test,C0019409;C0022885;C0039593;C0242960;C0392366;C0456984;C1515976;C1521798;C3831328;C4318744;C4554533
-1,hemorrhagic stroke ( n = nmbr ),C0053917;C0553692;C1334884
-1,hematologic,C0018943;C0205488
-1,heavy calcification,C0006660;C0006663;C0175895;C0439539;C1533591;C1879982;C2242558
-1,heart rate ( b . p . m . )  mean ± sd,C0018810;C0369637;C0441923;C0444504;C2347634;C2348143;C2699239
-1,heart rate  mean ± sd ( b . p . m . ),C0018810;C0369637;C0441923;C0444504;C2347634;C2348143;C2699239
-1,heart failure criteria met,C0018801;C0018802;C0243161;C4554158
-1,health state index score  uk algorithm,C0002045;C0041700;C0449820;C0600653;C0683314;C0918012;C1552854;C1553907;C1637833;C2986546;C4050231
-1,health - related quality of life,C4279947
-1,headache,C0018681;C4553197
-1,hdl < nmbr / nmbr mg / dl ( nmbr . nmbr / nmbr . nmbr mmol / l ) for men / women,C0025266;C0043210;C0053917;C1334884;C3642216;C3715113;C3898312
-1,hctz = hydrochlorothiazide . * based on wilcoxon nmbr - sample rank - sum tests for age and body mass index  t tests for systolic and diastolic blood and ' / nmbr tests for categorical variables . t data were missing for some patients .,C0020261
-1,hbanmbrc in patients with baseline hbanmbrc > nmbr % to < nmbr % ( > nmbr to < nmbr mmol / mol )  % [mmol / mol]  la  n baseline ( sd ) adjusted mean change ( nmbr % ci ) placebo subtracted change ( se ),C0030705
-1,hbanmbrc distribution at baseline  n ( % ),C0168634;C0520511;C1442488;C1704711
-1,hbanmbrc distribution,C0520511;C1704711
-1,hbanmbrc at baseline  %,C0168634;C1442488
-1,hba  % nmbrc,C0019016;C1825777;C3538758
-1,hawaiian / pacific,C0337920
-1,haemodynamics and lv function,C0019010;C4281788
-1,grouped region,C0017446;C0205147;C0439745;C4319846
-1,group — no . ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
-1,grip strength ( kg ),C0022718;C0429271;C0439209;C2598165;C4054209
-1,gpiib / iiia receptor inhibitor,C0016011;C0597357;C1999216
-1,gold group d — no . ( % ) | |,C0018026;C0441838;C1304897
-1,glycemic drugs,C0005802;C0013227;C3687832
-1,glyburide ( n = nmbr ),C0017628;C0053917;C1334884
-1,glyburide,C0017628
-1,glucose - lowering therapies,C0017725;C0087111;C0441994;C2003888
-1,glucose  mmol / l,C0017725;C1532563
-1,glucocorticoids plus immunosuppressive agents,C0017710;C0021081;C3540777;C3540778
-1,glucocorticoids and immunosuppressants,C0017710;C3540777;C3540778
-1,glp - nmbr receptor agonist ( other than study drug ),C0013175;C0018301;C0053917;C1334884;C1422069;C1425391;C1539338;C2350813;C4543206
-1,glomerular,C0022663;C0268731
-1,gliclazide ( modified release ) 一 no . ( % ) ^,C0017631
-1,glargine,C0907402
-1,geometric mean of baseline,C0168634;C1442488;C2986759
-1,geometric mean crp concentration ( mg / l ),C0086045;C0439268;C1446561;C2986759;C3827302;C3890735;C4048285
-1,geographical region ( % ),C0017446
-1,geographic region — no . ( % ),C0017446
-1,geographic region - north america,C0017446;C0028405
-1,geographic region - europe,C0015176;C0017446
-1,geographic region  %,C0017446
-1,gender ( % ) male / female,C0043210;C0079399;C0086287;C0086582;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429
-1,gender  women n  % ),C0043210;C0079399;C1522384
-1,gender  % of patients,C0030705;C0079399;C1522384
-1,gemfibrozil,C0017245
-1,gastrointestinal area involved — no . / total no . ( % ),C0017446;C0205146;C0521362
-1,gallbladder - related aes,C0016976;C0439849;C0445223;C1412268;C2699274
-1,galectin - nmbr ( ng / ml ),C0053917;C0439275;C0607430;C1334884
-1,functional assessment of chronic illness,C0008679;C0278372
-1,full analysis set,C0002778;C0036849;C0443225;C0936012;C1442518;C1524024;C1705195
-1,free fatty acids ( mmol / l ),C0015688;C1532563
-1,frailty status,C0424594;C0449438
-1,formoterol nmbr gg bid,C0017454;C0018370;C0053917;C0060657;C1334884
-1,fish oil,C0016157
-1,first mace,C0205435;C0349381;C0949745;C1279901;C1445339
-1,first - generation stentt,C0079411;C0205435;C1279901;C3146294
-1,filtration rate nmbr - nmbr,C0016107;C0053917;C0871208;C1334884;C1521828
-1,fibrinolytic for qualifying event,C0040044;C0441471;C1514624;C4019010
-1,fibrinogen ( pmol / l ) c,C0016006;C0439284;C1167394;C2587184;C3540039
-1,fibrinogen  g / l,C0016006;C0439294;C0456615;C1167394;C2587184;C3540039
-1,fibrinogen,C0016006;C1167394;C2587184;C3540039
-1,fibrin - specific,C0015982
-1,ff / vi nmbr / nmbr pg od,C0030827;C0053917;C0072225;C0205999;C0229089;C0439164;C1266240;C1334884;C1512019;C3273373;C3665488;C4554348
-1,ff / vi nmbr / nmbr gg ( n = nmbr  nmbr ),C0017454;C0018370;C0053917;C0205999;C1334884;C4554348
-1,fevnmbr reversibilityz ( pre / post ipratropium )  %,C0027235;C0332152;C0687676;C0740175;C1704687;C2257086;C3469826;C3669034
-1,fevnmbr / fvc ( post salbutamol ),C0001927;C0687676;C1704687;C3469826;C3714541
-1,fevnmbr / fvc ( post - albuterol ),C3714541
-1,fevnmbr / fvc  %  mean ( sd ) nmbr,C0053917;C0444504;C1334884;C2347634;C2348143;C2699239;C3714541
-1,fevnmbr  litres ( post - salbutamol )  mean ( sd ),C0001927;C0444504;C0475211;C0687676;C1704687;C2347634;C2348143;C2699239;C3469826
-1,fenofibric acid + moderate - dose statin,C0060179;C0360714;C1709056
-1,feno placebo ( lsm ),C0032042;C1696465;C1706408
-1,femoral neck,C0015815
-1,femoral access — no . / total no . ( % ),C0015811
-1,female race / ethnicity,C0015031;C0034510;C0043210;C0086287;C0243103;C1705497;C1705498;C1706779;C3853635
-1,fatigue,C0015672;C3463815;C4050243;C4554645
-1,fasting plasma insulin — mu / liter,C0015663;C0028971;C0347978;C0475211;C0857690;C3714918
-1,fasting plasma glucose  mg / dl  mean ( sd ) b,C0015663;C0202042;C0439269;C0444504;C0455280;C2347634;C2348143;C2699239
-1,fasting glucose  mmol / l  mean ± sd,C0015663;C0017725;C0444504;C1532563;C2347634;C2348143;C2699239
-1,fasting free fatty acids ( ^mol / liter ),C0015663
-1,fasting c - peptide  ng / ml,C0006558;C0015663;C0439275
-1,fastest third,C0015663;C0205437;C0456962;C2985769
-1,family history of venous thromboembolism ( % ),C0015576;C0042449;C0241889;C0348013;C0455533;C1704727;C1997614
-1,family history of cad ( diagnosed at < nmbr yr of age ) — no . ( % ) cigarette smoker — no . ( % ),C0241889;C1504769;C2239547;C3813548;C4284121
-1,ezetimibe use,C0042153;C0457083;C1142985;C1947944
-1,ezetimibe nmbr mg + statin ( n = nmbr  nmbr ),C0024671;C0026410;C0053917;C0360714;C0439269;C1142985;C1334884;C1960952;C2346927;C4321396;C4521761
-1,ezetimibe / simvastatin nmbr / nmbr mg ( n = nmbr ),C0024671;C0026410;C0053917;C0439269;C1334884;C1532737;C1960952;C2346927;C4321396;C4521761
-1,ezetimibe + simvastatin ( n = nmbr * ),C0053917;C1334884;C1532737
-1,ezetimibe,C1142985
-1,eze / simva gender,C0079399;C1522384
-1,extended - duration enoxaparin  n / n ( % ),C0206460;C0231448;C0231449;C0439792;C0449238;C2926735
-1,exercise times per week  ( minimum,C0015259;C0456698;C1522704;C1524031;C1552614;C2826545
-1,exercise,C0015259;C1522704
-1,exenatide n = nmbr,C0053917;C0167117;C1334884
-1,exenatide,C0167117
-1,european union,C0015179
-1,european trial,C0008976;C0239307;C1535514
-1,europe nmbr ( n = nmbr ),C0015176;C0053917;C1334884
-1,europe / lsrael,C0015176
-1,europe ( non - eu ),C0015176;C0015179;C1518422;C3665627
-1,etoricoxib nmbr mg n = nmbr n ( % ),C0024671;C0026410;C0053917;C0439269;C0972314;C1334884;C1960952;C2346927;C4321396;C4521761
-1,etoricoxib dose,C0178602;C0869039;C0972314;C1114758
-1,ethnicity ( % ),C0015031;C0243103
-1,ethnic origin  n ( % ),C0015031
-1,ethnic origin,C0015031
-1,ethnic group — no . ( % ) ',C0015031;C1879937
-1,etanercept ( n = nmbr ),C0053917;C0717758;C1334884
-1,etanercept,C0717758
-1,estimated glomerular filtration rate < nmbr ml / min / nmbr . nmbr mnmbr : i : §,C0021966;C0023806;C0053917;C0221138;C0439445;C0702093;C1334884;C1524029;C3811844;C3813700
-1,erythrocyte sedimentation rate — mm / hr | |,C1176468;C1619634;C4330985;C4554674
-1,epa / aa ratio,C0282379;C0456603;C1235746;C1547037;C1882141;C4554792
-1,enrollment in lmwh,C0019139;C1516879;C1696073;C3536766;C3888021
-1,enoxaparin / vka,C0206460
-1,enoxaparin,C0206460
-1,energy / fatigue,C0015672;C0424589;C0542479;C1442080;C3463815;C4050243;C4330907;C4554645
-1,endothelin nmbr ( pg / ml ),C0053917;C0079284;C0439297;C1334884
-1,endothelin - receptor antagonists plus phosphodiesterase type nmbr inhibitors,C0031638;C0053917;C0332307;C1134681;C1334884;C1547052;C1656262;C2266875;C3539996
-1,endothelin - receptor antagonists,C1134681;C2266875
-1,endoscopy subscore,C0014245
-1,enalapril + aliskiren dm = nmbr non - dm = nmbr,C0011816;C0014025;C0053917;C1120110;C1334884;C1518422;C3250443
-1,enalapril,C0014025
-1,emphysema ( % ),C0013990;C0034067
-1,emotional status,C0013987;C0449438;C0849912
-1,emotional role,C0013987;C0035820;C0849912;C1705810;C3871154
-1,elderly ( > nmbr years ),C0001792;C0053917;C0439234;C1334884;C1999167
-1,egfr  ml / min / mnmbr,C0439445;C1739039;C3811844;C3812682
-1,dyspnoea - mmrc grade  n ( % ),C0013404;C0441800;C0919553;C1963100;C3244287;C3826977
-1,dyspepsia,C0013395;C4552968
-1,duration of ra ( time from symptom onset )  years,C0040223;C0449238;C2926735;C3538806;C3541383;C4048756
-1,duration of psoriasis  years,C0033860;C0439234;C0449238;C2926735
-1,duration of last qualifying episode of atrial fibrillation > nmbr days,C0004238;C0053917;C0332189;C0344434;C0439228;C0449238;C1334884;C1514624;C1963067;C2926735
-1,duration of hypertension ( years ),C0020538;C0439234;C0449238;C1963138;C2926735
-1,duration of hypertension  n ( % ),C0020538;C0449238;C1963138;C2926735
-1,duration of diabetes mellitus  y,C0011849;C0449238;C2926735
-1,duration of crohn ' s disease ( yrs ),C0010346;C0449238;C2926735
-1,duration of coronary artery disease — yr,C0018787;C0439234;C0449238;C0852949;C2926735
-1,duration of clopidogrel pretreatment 一 hr median,C0070166;C0449238;C0549183;C0876920;C1550147;C2347635;C2348144;C2709094;C2926735;C2939193;C3539075;C3539076
-1,drugs used in diabetes  n ( % ),C0013227;C3687832
-1,drug - related teaesnmbr,C0013227;C0439849;C0445223;C1254351
-1,draining cutaneous fistula at baseline  n ( % ),C0013103;C0180499;C4265177
-1,doubling of creatinine †,C0010294;C0205173;C1561535;C1705764
-1,double - vessel disease  n ( % ),C0042373;C0205173;C1705764;C1705765
-1,documented asymptomatic cardiac ischemiac,C0018787;C0231221;C1301725;C1522601;C1609436
-1,dmard | |,C0242708
-1,diuretic — no . / total no . ( % ),C0012798
-1,diuretic agent,C0012798;C0450442;C1254351;C1521826
-1,disease and quality - of - life scores,C0012634
-1,disease - progression composite outcome !,C0205199;C0242656;C0449258;C0679250;C1274040;C1335499;C1547335;C1947900;C3542417;C4552808
-1,disease,C0012634
-1,dipyridamole,C0012582
-1,diltiazem or verapamil,C0012373
-1,dihydropyridine,C0012315;C0220821
-1,digitalis,C0012252;C0304520
-1,digital clubbing  n ( % ),C0009080;C0149651
-1,difference ( tiotropium - placebo ) ml ( nmbr % ci ),C0008107;C0032042;C0053917;C0213771;C0439526;C1334884;C1696465;C1705224;C1705241;C1705242;C1706408;C3259781;C3887665
-1,diastolic blood pressure ( mm hg ) medications,C0013227;C0428883;C0439475;C0802604;C1305849;C2598133;C4284232
-1,diarrhea,C0011991;C1963091;C3641756;C4084784;C4084802;C4085317
-1,diameter stenosis  mean ( sd )  %,C0552409;C0678234;C1261287;C2632116;C2699239
-1,diabetic treatments !,C0087111;C0241863
-1,diabetes with target organ disease *,C0011847;C0011849;C0012634;C0178784;C1521840;C2986546
-1,diabetes durationa < median,C0011847;C0011849;C0549183;C0876920;C2347635;C2348144;C2939193
-1,diabetes duration ( known )  % of patients,C0011847;C0011849;C0449238;C2926735
-1,detemir / insulin glargine  %,C0537270;C0907402
-1,des ( % previous stenting ),C0011702;C0038257;C0205156;C1552607;C2348535;C4551552
-1,depressed and low perceived social support,C0344315;C0549249
-1,denosumab ( n = nmbr ),C0053917;C1334884;C1690432
-1,death or stent thrombosis,C0011065;C1306577;C4082313;C4552775
-1,death or myocardial infarction,C0011065;C1306577;C4082313;C4552775
-1,death or absolute fvc decrease > nmbr %,C0011065;C1306577;C4082313;C4552775
-1,death from any cause,C0007465
-1,death  mi  idr  st  or any timi bleeding,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
-1,death  mi  idr  or st,C0011065;C1306577;C3810814;C4082313;C4552775
-1,death  large mi,C0011065;C0549177;C1306577;C3810814;C4082313;C4552775
-1,das - nmbr ( crp ) < nmbr . nmbr  n ( % ),C0051767;C0053917;C0057671;C1334884;C3890735;C4048285
-1,daily insulin dose  mean ( sd )  iu,C0021641;C0049272;C0332173;C0366513;C0439453;C0444504;C0694756;C1533581;C1579433;C2347634;C2348070;C2348143;C2699239;C3714501
-1,d - dimer levelsatinclusion,C0060323
-1,cyclosporine ( n = nmbr ),C0010592;C0010594;C0053917;C1334884
-1,cvd risk factors ( age > nmbr ),C0001779;C0001783;C0007222;C0035647;C0035648;C0053917;C1334884;C1553898;C4552904
-1,cvd or mi,C0007222
-1,cv medication  % of patients,C0013227;C0030705;C3244316;C3538987;C4048877;C4284232;C4318503
-1,cv event  years,C0439234;C0441471;C3538987;C4019010;C4048877;C4318503
-1,cv death / mi / stroke,C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100
-1,cv death + hf hospitalization,C0011065;C0018488;C0019993;C1306577;C1313497;C1538440;C3273279;C3538987;C4048877;C4082313;C4318503;C4552775
-1,currentother ( notpredefined ) medical conditions,C0012634;C0199168;C0205476;C0348080;C1705253;C3864998
-1,current tobacco abuse  n ( % ),C0040336;C0521116;C1705970
-1,current atrial fibrillation or flutter on ecg,C0004238;C0344434;C0521116;C1705970;C1963067
-1,ctn - l  ng / ml,C0439275;C0917591
-1,ct or mr scan of the brain *,C0007673;C3540513;C3813556;C3888140
-1,crude analysis  n ( % ),C0002778;C0936012;C1524024
-1,crp concentration > nmbr . nmbr mg / dl ( nmbr mg / l )  n ( % ),C0053917;C0086045;C1334884;C1446561;C2827881;C3642216;C3827302;C3890735;C4048285
-1,cross - damp time : < l : llhrs : min ( n = nmbr ),C0040223;C0053917;C0205381;C0702093;C1334884;C1524029;C2828360;C3541383;C3813700;C3891560
-1,crohn ’ s disease related surgery,C0010346
-1,crohn ' s disease - related medication at baseline  n ( % ),C0010346
-1,crohn ' s disease,C0010346
-1,creatinine ≥ nmbr . nmbr mg / dl,C0010294;C0053917;C0439269;C1334884;C1561535
-1,creatinine  mean ( sd )  mg / dl,C0010294;C0439269;C0444504;C1561535;C2347634;C2348143;C2699239
-1,coumadin,C0699129
-1,coronary artery bypass surgery,C0010055
-1,coronary angiography during the index hospital stay,C0002978;C0085532;C0428776;C0600653;C0918012;C1548829;C1552854;C1637833;C2986546;C3489408
-1,coronary angiography and intervention,C0085532;C1548829
-1,copd severity : severe / very severe,C0024117;C0439793;C0442824;C0522510;C1412502;C2984081;C3714496
-1,copd severity ( gold stage ),C0018026;C0024117;C0205390;C0439793;C0522510;C1300072;C1304897;C1306673;C1412502;C3714496
-1,copd or asthma,C0024117;C1412502;C3714496
-1,copd - rosuvastatin ( n = nmbr ),C0024117;C0053917;C0965129;C1334884;C1412502;C3714496
-1,control baseline ( n - nmbr ),C0053917;C0168634;C0243148;C1334884;C1442488;C1550141;C1882979;C2587213;C3274648;C4553389
-1,contrast nephropathy risk score,C0009924;C0022658;C0035647;C0449820;C1979874;C4050231;C4552904
-1,continued thienopyridine n = nmbr subjects,C0053917;C0549178;C1120149;C1334884
-1,continued thienopyridine n ( % ),C0549178;C1120149
-1,congestive heart failure — no . ( % ) | |,C0018802
-1,congestive heart failure  n ( % ),C0018802
-1,congenital shunts,C0009678;C0232180;C0542331;C1442858;C1744681
-1,concurrent treatment of crohn ' s disease at study entry — no . of patients ( % ) ff,C0010346;C0039798;C0087111;C0205420;C1522326;C1533734;C1705169;C3538994;C3887704
-1,concomitant mtx —,C0025677;C0521115;C1417487
-1,concomitant mtx use  n ( % ),C0025677;C0042153;C0457083;C0521115;C1417487;C1947944
-1,concomitant medications for ulcerative colitis — no . ( % ),C0009324;C0013227;C0521115;C0802604;C2598133;C4284232
-1,concomitant drugs,C0013227;C0521115;C3687832
-1,concomitant conventional dmard use,C0042153;C0242708;C0439858;C0457083;C0521115;C1947944
-1,concomitant atorvastatin dose  mg,C0024671;C0026410;C0178602;C0286651;C0439269;C0521115;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
-1,comparison with placebo ( mean,C0032042;C0444504;C1696465;C1706408;C1707455;C2347634;C2348143
-1,comparison with baseline ( mean,C0168634;C0444504;C1442488;C1707455;C2347634;C2348143
-1,comorbidities other than diabetes,C0009488;C0011847;C0011849
-1,comorbid diseasesa diabetesb,C0009488
-1,community hospital ( % ),C0020003
-1,combined trials,C0008976;C0205195
-1,coenzyme qnmbr  ^g / ml #,C0009235;C1300565
-1,clopidogrel no . of patients % ),C0070166
-1,clopidogrel dose on / before pci,C0070166;C0178602;C0869039;C1114758;C4049621
-1,clopidogrel  %,C0070166
-1,claudication ( fontaine class > nmbr ),C0021775;C0053917;C0311395;C0456387;C1334884;C1456822;C1518526;C1705943
-1,claudication,C0021775;C0311395;C1456822
-1,classification of af  no . ( % ),C0008902;C0008903;C0344434;C0678229;C4049859
-1,cigarette users,C0677453;C1704760;C1706077;C3890423
-1,chronic obstructive pulmonary disease  n ( % ),C0024117
-1,chronic obstructive pulmonary disease,C0024117
-1,chronic heart failure,C0018802;C0264716
-1,chondroitin sulfate ( n = nmbr ),C0008466;C0053917;C1334884
-1,cholesterol absorption inhibitor ( ezetimibe ),C0000854;C0003277;C1142985;C1999216;C2347023;C2347080;C2698776;C2825050;C2945742
-1,cholesterol  ( . nmbr . nmbr mmol / l )  n ( % ),C0008377;C0053917;C1334884;C1532563
-1,chf history,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
-1,chd + cerebral infarction,C0007785;C0280604;C3542407
-1,characteristics of pulmonary embolism at inclusion,C0034065;C1521970
-1,change from baseline in hbanmbrc ( % ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
-1,change from baseline in dasnmbr - esr  meannmbr sd,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
-1,change from baseline  adjusted mean ( nmbr % ci )  %,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
-1,certolizumab group ( n = nmbr ),C0053917;C0441848;C1334884;C1872109
-1,cerebrovascular disorders  n ( % ),C0007820
-1,cerebrovascular disease  n ( % ),C0007820
-1,central / eastern europe and russia hr ( nmbr % cl ),C0015177;C0205099;C0682369;C1707877;C1879652
-1,central / eastern europe / russia,C0015177;C0035970;C0205099;C0682369;C1707877;C1879652
-1,celecoxib ( n = nmbr ),C0053917;C0538927;C1334884
-1,ccv history / condition at baseline,C0168634;C0683519;C1442488
-1,ccbs  ( % ),C0006684
-1,caucasian ethnicity,C0007457;C0015031;C0043157;C0243103
-1,carotid stenosis,C0007282
-1,cardiovascular medications  %,C0007220
-1,cardiovascular medications,C0007220
-1,cardiovascular inclusion criteriat,C0007226;C0007637;C1512693;C3887460
-1,cardiovascular hospitalization,C0007226;C0019993;C3887460
-1,cardiovascular disease,C0007222
-1,cardiovascular and respiratory,C0007226;C3887460
-1,cardiac resynchronization therapy,C1167956
-1,cardiac history  %,C0018787;C0019664;C0019665;C0262512;C0262926;C1522601;C1705255;C2004062
-1,cardiac - biomarker status — no . / total no . ( % ) $,C0005516;C0018787;C0449438;C0449442;C1271630;C1522601;C1999091;C2735302
-1,cangrelor  %,C1121991
-1,candesartan nmbr / nmbr,C0053917;C0717550;C1334884
-1,cancer ( n = nmbr ),C0006826;C0053917;C0998265;C1306459;C1334884
-1,canakinumab,C2718773
-1,calcium channel blockers  n ( % ),C0006684;C2757014
-1,calcium channel antagonists  n ( % ),C0006684;C2757014
-1,calcium antagonists  n ( % ),C0006684
-1,calcium - channel blockers ( % ),C0006684;C2757014
-1,calcium - channel blocker ( ratelowering ),C0006684;C3536851;C4521885
-1,cad history and risk factors  n ( % ),C0019664;C0019665;C0262512;C0262926;C1504769;C1705255;C2004062;C2239547;C3813548;C4284121
-1,cad and abi < nmbr - nmbr §,C1504769;C2239547;C3813548;C4284121
-1,cabg surgery,C0010055;C0038894;C0038895;C0543467;C1274039
-1,cabg or pci,C0010055
-1,cabg > nmbr month ago,C0010055;C0053917;C0332177;C0439231;C1334884
-1,c - peptide  median ( ql  qnmbr )  nmol / l,C0006558;C0439282;C0549183;C0876920;C2347635;C2348144;C2939193
-1,bursitis,C0006444
-1,bronchitis,C0006277
-1,both ptca and cabg,C2936173
-1,bosentan ( n = nmbr ),C0053917;C0252643;C1334884
-1,body mass index > nmbr kg / mnmbr  n ( % ),C0005893;C0022718;C0053917;C0439209;C0578022;C1305855;C1334884;C4054209
-1,body mass  kg,C0022718;C0439209;C0518010;C4054209
-1,body - mass index  !  waist - to - hip ratio,C0005893;C0205682;C0578022;C1305855
-1,bnp  median ( iqr )  pg / ml,C0054015;C0439297;C0549183;C0876920;C1095989;C1417808;C2347635;C2348144;C2939193;C2982014
-1,bmi ( kg / mnmbr ) cardiac parameters,C0018787;C0022718;C0439209;C0449381;C0578022;C1522601;C4054209
-1,bmi ( kg / mnmbr ) [median ( nmbrth to nmbrth percentile ) ],C0022718;C0439209;C0549183;C0876920;C2347635;C2348144;C2923536;C2939193;C4054209
-1,blood urea nitrogen ( mg / dl ),C0005845;C0439269;C0600137
-1,blood pressure - lowering treatment,C0005823;C0033095;C0039798;C0087111;C0441994;C0460139;C0596197;C1271104;C1272641;C1306345;C1522326;C1533734;C1705169;C2003888;C3538994;C3887704;C4284008
-1,blood pressure  mean ( sd ) [range]  mm hg,C0428886;C0439475;C1514721;C2348147;C2699239;C3542016
-1,blood pressure,C0005823;C1271104;C1272641
-1,blood oxygenation  mean ± sd,C0005767;C0005768;C0229664;C0231940;C0282636;C0444504;C2347634;C2348143;C2699239
-1,blood leukocyte count ( nmbr cells per l ),C0023508;C0023516;C0053917;C0347983;C0427512;C1334884
-1,blood eosinophils count,C0014467
-1,black race,C0005680
-1,bivariate frailty model ( statin users vs non - users ),C0360714;C0424594;C1706077;C3161035;C3274659;C3714583;C3853906
-1,biomarker low ( periostin < nmbr ng / ml or blood eosinophils < nmbr cells per pl )  na,C0005516;C0053917;C0205251;C0219433;C0439275;C1334884;C1424662;C1550472;C3812270;C3890211;C4048187;C4321351;C4522223
-1,biologic naive,C0005515;C0205460
-1,biologic agents,C0005515
-1,beta - blockers ( all )  n ( % ),C0001645
-1,beta - blocker — no . ( % ),C0001645
-1,beta - blocker at last follow - up |,C0001645;C0589120;C1522577;C1704685;C3274571
-1,beta - blocker ( except sotalol ),C0001645;C0037707
-1,beta - adrenergic blocker,C0001645;C2757061;C3536830
-1,benralizumab nmbr mg qnmbrw ( n = nmbr ),C0024671;C0026410;C0053917;C0439269;C1334884;C1960952;C2346927;C2982078;C4321396;C4521761
-1,bdi total score ( baseline ),C0006448;C0168634;C0451022;C1442488;C2964552;C3714938;C3889415
-1,baseline tobacco use,C0040335;C0168634;C0543414;C0841002;C1442488;C3853727
-1,baseline systolic bp,C0168634;C0871470;C1442488
-1,baseline statin usec,C0168634;C0360714;C0439224;C1442488
-1,baseline sitosterol,C0037215;C0168634;C0220914;C1442488
-1,baseline sgrq score,C0168634;C1442488
-1,baseline scales  median ( range ),C0168634;C1442488
-1,baseline pulmonary medication  n ( % ),C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268
-1,baseline post - bronchodilator % predicted fev  < nmbr %,C0168634;C1442488
-1,baseline nmbr - h ppg ,C0033727;C0053917;C0168634;C0369286;C0441932;C0564385;C1334884;C1418888;C1442488;C4528284
-1,baseline nihss score ( % ) #,C0168634;C1442488;C1697238
-1,baseline nihss score  median ( range ),C0168634;C1442488;C1697238
-1,baseline medical therapy,C0168634;C0418981;C1442488
-1,baseline median ( iq range ),C0168634;C0549183;C0876920;C1442488;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
-1,baseline mean ( sd )  % [mmol / mol],C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C3829066
-1,baseline lp ( a ) in nmbr classes,C0053917;C0065058;C0168634;C0456387;C1334884;C1439335;C1442488;C1518526;C1705943;C4019422;C4553379
-1,baseline killip class,C0168634;C1442488;C1881332
-1,baseline ics use  n ( % ),C0168634;C0815320;C1442488;C4551720
-1,baseline hematocrit  median ( iqr ),C0018935;C0168634;C0518014;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
-1,baseline heart rate,C0018810;C0168634;C1442488
-1,baseline heart failure severity nyha class i,C0018801;C0018802;C0168634;C0439793;C0522510;C1442488;C1882084;C4554158
-1,baseline hb < nmbr g nmbr nmbr n = nmbr,C0053917;C0062408;C0168634;C0439267;C1334884;C1442488
-1,baseline fpg ,C0168634;C1442488
-1,baseline ezetimibe usec,C0168634;C0439224;C1142985;C1442488
-1,baseline ecrcl,C0168634;C1442488
-1,baseline disease and quality - of - life scores,C0012634;C0168634;C1442488
-1,baseline diabetes,C0011847;C0011849;C0168634;C1442488
-1,baseline corticosteroids *,C0001617;C0168634;C1442488;C3539185;C3540725;C3540726;C3540727
-1,baseline copd exacerbation history  * n ( % ),C0019664;C0019665;C0168634;C0262512;C0262926;C0740304;C1442488;C1705255;C2004062
-1,baseline cardiovascular medication  c n ( % ),C0007220;C0168634;C1442488
-1,baseline cardiac biomarkers elevated,C0168634;C1442488;C2735101;C2735102
-1,baseline cardiac biomarkers,C0168634;C1442488;C2735101;C2735102
-1,baseline bmi nmbr to < nmbr kg / mnmbr  n = nmbr,C0022718;C0053917;C0168634;C0439209;C0578022;C1334884;C1442488;C4054209
-1,baseline : < nmbr . nmbr meq / l eos : > nmbr . nmbr or < nmbr . nmbr meq / l,C0053917;C0168634;C0439375;C1334884;C1442488;C1623465;C1861303
-1,baseline / concomitant therapies,C0168634;C1442488;C1707479
-1,baricitinib  nmbr mg daily ( n = nmbr ),C0024671;C0026410;C0053917;C0332173;C0439269;C1334884;C1960952;C2346927;C4044947;C4321396;C4521761
-1,balloon angioplasty plus abciximab,C0002996;C0002997;C0288672;C0332287
-1,azathioprine ( n = nmbr ),C0004482;C0053917;C1334884
-1,available baseline blood specimen n,C0168634;C0178913;C0470187;C1442488
-1,atv nmbr mg study protocol,C0024671;C0026410;C0053917;C0210243;C0439269;C0674679;C1145759;C1334862;C1334884;C1507394;C1960952;C2346927;C2348563;C2599718;C4321396;C4521761
-1,atrial flutter,C0004239;C0344423;C1963068
-1,atrial fibrillation onset,C0004238;C0206132;C0332162;C0344434;C1963067
-1,atrial fibrillation  n ( % ),C0004238;C0344434;C1963067
-1,atrial fibrillation  duration — no . ( % ),C0004238;C0344434;C0449238;C1963067;C2926735
-1,atorvastatin ls means difference nmbr mg ( nmbr % ci ) a ( n = nmbr ),C0008107;C0023668;C0024671;C0026410;C0053917;C0286651;C0439269;C1334884;C1704970;C1705241;C1705242;C1960952;C2346927;C3259781;C4321396;C4521761
-1,atorvastatin dose,C0178602;C0286651;C0869039;C1114758
-1,atorvastatin  n ( % ),C0286651
-1,atenolol strategy,C0004147;C0679199
-1,atenolol *,C0004147
-1,associated with hiv infection,C0019693;C0332281
-1,associated with connective tissue disease,C0009782;C0332281
-1,aspirin use ( > nmbr mg ),C0004057;C0024671;C0026410;C0042153;C0053917;C0439269;C0457083;C1334884;C1947944;C1960952;C2346927;C4321396;C4521761
-1,aspirin group ( n = nmbr nmbr ) ( nmbr nmbr person years ),C0004057;C0027361;C0053917;C0439234;C0441848;C1334884;C2347489
-1,aspirin group,C0004057;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
-1,aspirin but no ppi,C0004057
-1,aspirin at last follow - up,C0004057;C0589120;C1522577;C1704685;C3274571
-1,aspirin and ppi,C0004057
-1,aspirin and other antiplatelet,C0004057
-1,aspirin / other antiplatelet agents  n ( % ),C0004057
-1,aspirin / antiplatelet,C0004057
-1,asia - pacific hr ( nmbr % cl ),C0003980;C0053917;C0596019;C1334884
-1,asastoppedat randomization  n,C0034656
-1,arthritis,C0003864;C4552845
-1,argentina,C0003761;C1504311
-1,apremilast nmbr mg bid n = nmbr,C0024671;C0026410;C0053917;C0439269;C1334884;C1678805;C1960952;C2346927;C4321396;C4521761
-1,apolipoprotein b^,C0003593
-1,apoa - nmbr  g / l,C0003592;C0053917;C0439294;C0456615;C0523508;C1334884;C4553344;C4553379
-1,apo b ( mg / dl ) - mean ± sd,C0003593;C0439269;C0444504;C2347634;C2348143;C2699239;C3252643
-1,apixaban vs . placebo,C1831808
-1,apixaban  nmbr . nmbr mg,C0024671;C0026410;C0053917;C0439269;C1334884;C1831808;C1960952;C2346927;C4321396;C4521761
-1,apixaban,C1831808
-1,aortic stenosis  n ( % ),C0003507
-1,aortic stenosis,C0003507
-1,any statin + other llt,C0360714
-1,any relevant infarct,C0021308;C2347946
-1,any pulmonary medication,C0013227;C0024109;C2707265;C2709248;C3244316;C4284232;C4522268
-1,any prior anti - tnf treatment failure,C0162643;C0231174;C0235828;C0332152;C0521983;C0680095;C1448177;C1514463;C1547544;C2826257
-1,any immunosuppressive agent,C0021081
-1,any disease,C0012634
-1,any cardiovascular disease history  n ( % ),C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460
-1,any albuminuria — no . ( % ),C0001925
-1,antithrombotic agents  n ( % ),C1704311
-1,antithrombotic / coagulant,C0009117
-1,antimalarials only,C0003374;C0205171;C1720467
-1,antihypertensive treatment,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
-1,antihypertensive medication or,C0003364
-1,antihypertensive drug  %,C0003364
-1,antihypertensive  antianginal  and other cardiovascular medications,C0003364;C1874267;C3537168
-1,antihyperglycemic oral agent therapy,C0020616;C0039798;C0087111;C0442027;C0450442;C1254351;C1363945;C1521826;C4521986
-1,antihyperglycemic,C0020616
-1,antidiabetic medication | |,C0935929
-1,anti - ischaemia agents *,C0022116;C0040616;C4321499
-1,anti - inflammatory drugs,C0003209
-1,anti - cholinergics ( short - acting ) a,C0242896
-1,anti - cholinergics ( long - acting ),C0242896
-1,anti - ccp antibody positive,C0741132;C4318437
-1,ankle - brachial index < nmbr . nmbr — no . ( % ),C0053917;C1328319;C1334884;C3888326
-1,angiotensin receptor blocker and / or ace,C0034787;C1622222
-1,angiotensin - converting enzyme or angiotensin receptor blocker,C0022709;C1452534
-1,angiotensin - converting enzyme inhibitors / angiotensin receptor blockers,C0003015;C0597357;C2757044
-1,angiotensin - converting enzyme inhibitor or angiotensin receptor blocker,C0003015;C2757044;C3536837;C4541021
-1,angiotensin - converting - enzyme inhibitor or angiotensin - receptor blocker §,C0003015;C2757044;C3536837;C4541021
-1,angiography — no . ( % ),C0002978
-1,angiography during index hospitalization,C0002978;C0019993;C0600653;C0918012;C1552854;C1637833;C2986546
-1,angiographic data,C0002978;C1511726;C3245479;C3714741
-1,angiographic complications  site - reported — no . / total no . ( % ),C0002978;C0009566;C0205145;C1171258;C1515974;C2825164
-1,angiogenin ( ng / ml ),C0051844;C0439275;C1367482
-1,angina pectoris — no . ( % ),C0002962
-1,angina class at baseline,C0002962;C0168634;C0456387;C1442488;C1518526;C1705943
-1,anemia — no . ( % ) | |,C0002871;C1000483;C4554633
-1,ancestry ( % ) f,C0016327
-1,amlodipine / valsartan nmbr / nmbr mg / v = nmbr,C0024671;C0026410;C0053917;C0439269;C1334884;C1960952;C1962523;C2346927;C4321396;C4521761
-1,aml / val nmbr / nmbr mg,C0023465;C0023467;C0024671;C0026410;C0042285;C0053917;C0439269;C0523975;C1334884;C1960952;C2346927;C4321396;C4521761
-1,amiodarone vs . placebo no . hazard ratio ( nmbr . nmbr % cl ),C0002598
-1,amiodarone  n ( % ),C0002598
-1,amiodarone,C0002598
-1,american indian or native alaskan,C0002460
-1,american indian or alaska,C0002460
-1,all ~ cause mort / hf hosp .,C0015127;C0018488;C1313497;C1524003;C1538440;C3273279;C3815322
-1,all with coenzyme qnmbr ( n = nmbr  nmbr ),C0009235;C0053917;C1334884
-1,all randomized patients ( range ),C0030705;C0034656;C1514721;C2348147;C3542016;C3815594
-1,all patients with fistulas ( n = nmbr ),C0016169;C0030705;C0053917;C1334884
-1,all cardiovascular,C0007226;C3887460
-1,aliskiren ( n = nmbr ),C0053917;C1120110;C1334884
-1,aldosterone inhibitor,C0002007
-1,aldosterone blocker  %,C0002006
-1,alcohol use ( > nmbr drink / wk ),C0001948;C0042153;C0053917;C0332174;C0439230;C0452428;C0457083;C0556297;C1334884;C1947944
-1,albuterol reversibility  %,C0001927;C0449261
-1,albuminuria ( g / g ),C0001925;C1319635
-1,aggressive ( n = nmbr ),C0001807;C0053917;C0580822;C1334884
-1,age at randomization ( years ),C0034656;C1510829
-1,age at first seizure  years  mean ( sd ),C0036572;C0205435;C0444504;C1279901;C1510829;C1959629;C2347634;C2348143;C2699239;C4553401
-1,adl subscale ( range  nmbr - nmbr ) *,C0001288;C0053917;C1334884;C1420005;C1514721;C2348147;C3542016
-1,adjusted mean change from baseline ( nmbr % ci )  % [mmol / mol],C0008107;C0053917;C0168634;C0392747;C0439190;C0443172;C0444504;C0456081;C0948922;C1334884;C1442488;C1705241;C2347634;C2348143;C3259781;C3829066;C4319952
-1,acute rheumatic disorders,C0001314
-1,acute dvt study,C0149871;C0205178;C0557651;C2603343;C2926618;C3899446
-1,acute coronary syndrome nmbr,C0053917;C0948089;C1334884
-1,active cancer at randomization  n ( % ),C0006826;C0034656;C0205177;C0998265;C1306459;C3853793;C3888249
-1,ace inhibitors or angiotensin ii blockers,C0003015
-1,ace inhibitors or angiotensin ii,C0003015
-1,ace inhibitor — no . ( % ),C0003015;C4541021
-1,ace inhibitor or arb at last follow - up,C0003015;C4541021
-1,ace inhibitor or arb at enrollment,C0003015;C4541021
-1,ace inhibitor monotherapy,C0003015;C4541021
-1,ace inhibitor at last follow - up,C0003015;C0589120;C1522577;C1704685;C3274571;C4541021
-1,ace - inhibitor use,C0003015;C0042153;C0457083;C1947944;C4541021
-1,accp bleeding risk at inclusion  no . ( % ) f,C0007637;C1512693;C3251812
-1,absolute risk difference ( ci )  % *,C0008107;C0035647;C1519101;C1549031;C1705241;C1705242;C3259781;C4552904
-1,abrupt vessel closure,C0005847;C0185003;C1276802;C1521802
-1,abnormal angiogram,C0002978;C0205161;C1548816;C2347472;C2699333;C3891555;C4255126
-1,abdominal or perianal fistula at baseline  n ( % ),C0000726
-1,abdominal aortic — no . ( % ),C0003484
-1,abatacept / open - label abatacept,C1619966;C1709323
-1,a mini - mental state examination  omega - nmbr fatty acids vs placebo,C0015684;C0053917;C0451306;C1334884;C1719844
-1,> nmbr years education,C0013621;C0013622;C0013658;C0039401;C0053917;C0439234;C1334884
-1,> nmbr ( ml ) additional angiography,C0002978;C0053917;C0439526;C1334884;C1524062;C1705224;C3887665
-1,> nmbr % stenosis of coronary  carotid  or lower extremity arteries,C0007282;C0018787;C0053917;C0242231;C0741968;C1334884
-1,< nmbr . nmbr mm hg diastolic blood pressure,C0053917;C0428883;C0439475;C1305849;C1334884
-1,% stenosis  as assessed by investigator,C0678234;C1261287;C2632116
